

G-PROTEIN COUPLED RECEPTOR (GPCR) TARGETING: TECHNOLOGIES AND GLOBAL MARKETS



BIO136A
August 2014

Ufuk Ezer
Project Analyst

ISBN: 1-56965-891-9

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
INTENDED AUDIENCE	3
SCOPE OF THE STUDY	3
METHODOLOGY AND INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	3
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE GLOBAL MARKET FOR GPCR DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET FOR GPCR DRUGS, 2010-2018 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	10
G PROTEIN-COUPLED RECEPTORS	10
HOW DO GPCRS INDUCE CELLULAR RESPONSES?	10
IMPORTANCE OF GPCRS IN DISEASE PHYSIOLOGY	11
GPCR TARGETING	11
CLASSIFICATION OF GPCR-TARGETING DRUGS	12
CLASS-A: RHODOPSIN-LIKE RECEPTOR TARGETING DRUGS	12
Peptide Receptor Drugs	13
Biogenic Amine Receptor Drugs	13
Hormone Receptor Drugs	13
Lipid-derived Ligand (Lipid and Phospholipid) Receptor Drugs	13
Nucleotide Receptor Drugs	14
CLASS B: SECRETIN RECEPTORS	14
Peptide Receptor Drugs	14
Hormone Receptor Drugs	14
CLASS C: METABOTROPIC GLUTAMATE RECEPTOR DRUGS	15
Proteinogenic Amino Acid Receptor Drugs	15
Ion Receptor Drugs	15
<i>TABLE 1 CLASSIFICATION OF THE GPCR-TARGETING DRUGS</i>	16
CHAPTER 4 REGULATORY ASPECTS	18
<i>TABLE 2 FDA-APPROVED GPCR TARGETING DRUGS, 2010-2014</i>	19
<i>TABLE 3 POSITIVE OPINION GRANTED BY THE EMA TO GPCR TARGETING DRUGS, 2012-2014</i>	21
<i>TABLE 4 BOX WARNINGS ENFORCED BY THE FDA FOR THE USE OF SELECTED GPCR-TARGETING DRUGS</i>	22
CHAPTER 5 GLOBAL MARKETS	27
MARKET ANALYSIS	27
<i>TABLE 5 GLOBAL MARKET FOR GPCR DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	28

TOPIC	PAGE NO.
<i>FIGURE 1 GLOBAL MARKET FOR GPCR DRUGS, 2010-2018 (\$ MILLIONS)</i>	28
RHODOPSIN-LIKE RECEPTOR DRUGS	29
Peptide Receptor Drugs	30
Angiotensin II Receptor Antagonists	30
Major Products	30
Angiotensin II Receptor Targeting Drugs in Development	31
<i>TABLE 6 ARB'S IN DEVELOPMENT, BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET</i>	31
Market Revenue	32
<i>TABLE 7 GLOBAL MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), THROUGH 2018 (\$ MILLIONS)</i>	33
<i>FIGURE 2 GLOBAL MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), 2010-2018 (\$ MILLIONS)</i>	33
Bradykinin Receptor Antagonists	33
Major Product	34
Market Revenue	34
<i>TABLE 8 GLOBAL MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	34
<i>FIGURE 3 GLOBAL MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	34
Opioid Receptor Targeting Drugs	35
Major Products (Opioids)	35
Major Products (Opioid Antagonists)	36
Opioids in Development	37
<i>TABLE 9 OPIOIDS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET</i>	37
Market Revenue	37
<i>TABLE 10 GLOBAL MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	38
<i>FIGURE 4 GLOBAL MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	38
Chemokine Receptor Antagonists	38
Major Products	39
Chemokine Receptor Antagonists in Development	39
<i>TABLE 11 CHEMOKINE RECEPTOR ANTAGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET</i>	40
Market Revenue	40
<i>TABLE 12 GLOBAL MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	40
<i>FIGURE 5 GLOBAL MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	40
Somatostatin Receptor Agonists	41
Major Products	41
Sandostatin Receptor Agonists in Development	42
<i>TABLE 13 SOMATOSTATIN RECEPTOR AGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET</i>	42
Market Revenue	43
<i>TABLE 14 GLOBAL MARKET FOR SOMATOSTATIN RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	43

TOPIC	PAGE NO.
<i>FIGURE 6 GLOBAL MARKET FOR SOMATOSTATIN RECEPTOR AGONISTS, 2010-2018 (\$ MILLIONS)</i>	43
Neurokinin Receptor Antagonists	43
Major Products	44
Market Revenue	44
<i>TABLE 15 GLOBAL MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	44
<i>FIGURE 7 GLOBAL MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	44
Vasopressin Receptor Antagonists	45
Major Products	45
Vasopressin Antagonists in Development	45
Market Revenue	46
<i>TABLE 16 GLOBAL MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	46
<i>FIGURE 8 GLOBAL MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	46
Endothelin Receptor Antagonists	46
Major Products	47
ERAs in Development	47
Market Revenue	48
<i>TABLE 17 GLOBAL MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	48
<i>FIGURE 9 GLOBAL MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	48
New Drug Classes in A-peptide Sub-class	48
Orexin Receptor Antagonists	48
Relaxin Receptor Agonists	49
Biogenic Amine Receptor Drugs	49
Muscarinic Receptor Targeting Drugs	49
Muscarinic Receptor Agonists	50
Muscarinic Agonists in Development	50
Muscarinic Receptor Antagonists	50
Major Products	50
Other Products	51
Muscarinic Receptor Antagonists in Development	51
Market Revenue	52
<i>TABLE 18 GLOBAL MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	52
<i>FIGURE 10 GLOBAL MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	52
Adrenergic Receptor Targeting Drugs	53
Alpha-Adrenergic Receptor Agonists	53
Alpha-Adrenergic Receptor Antagonists	53
Major Products	53
Beta-Adrenergic Receptor Agonists	54
Major Products	54
Beta-Adrenergic Receptor Antagonists	55
Major Products	55

TOPIC	PAGE NO.
Adrenergic Receptor Targeting Drugs in Development	55
Market Revenue	56
<i>TABLE 19 GLOBAL MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	56
<i>FIGURE 11 GLOBAL MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	57
Dopamine Receptor Targeting Drugs	57
Dopamine Receptor Agonists	57
Major Products	57
Dopamine Receptor Antagonists and Inverse Agonists	58
Major Products	58
Dopamine Receptor Targeting Drugs in Development	59
Market Revenue	60
<i>TABLE 20 GLOBAL MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	60
<i>FIGURE 12 GLOBAL MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	60
Histamine Receptor Antagonists	61
Major Products	61
Market Revenue	62
<i>TABLE 21 GLOBAL MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	62
<i>FIGURE 13 GLOBAL MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	63
Serotonin Receptor Targeting Drugs	63
Serotonin Receptor Agonists	63
Major Products	63
Serotonin Receptor Agonists in Development	64
Serotonin Receptor Antagonists	64
Major Products	64
Serotonin Receptor Antagonists in Development	65
<i>TABLE 22 SEROTONIN RECEPTOR ANTAGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET</i>	65
Market Revenue	66
<i>TABLE 23 GLOBAL MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	66
<i>FIGURE 14 GLOBAL MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	66
Hormone Receptor Drugs	67
Follicle Stimulating Hormone (FSH) Receptor Agonists	67
Major Products	67
Luteinizing Hormone (LH) Receptor Agonists	67
Major Product	67
Gonadotropin Releasing Hormone (GnRH) Receptor Agonists	67
Major Products	68
Market Revenue	68
<i>TABLE 24 GLOBAL MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	69
<i>FIGURE 15 GLOBAL MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	69

TOPIC	PAGE NO.
Lipid and Phospholipid Receptor Drugs	70
Eicosanoid Receptor Agonists	70
Major Product (Prostaglandins)	70
Major Products (Leukotriene)	71
Prostaglandin and Prostacyclin Receptor Agonists in Development	71
<i>TABLE 25 EICOSANOID RECEPTOR AGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET</i>	72
Market Revenue	72
<i>TABLE 26 GLOBAL MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	72
<i>FIGURE 16 GLOBAL MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	72
S1P Receptor Modulators	73
Major Product	73
S1P Receptor Modulators in Development	74
<i>TABLE 27 S1P RECEPTOR MODULATORS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET</i>	74
Market Revenue	74
<i>TABLE 28 GLOBAL MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	74
<i>FIGURE 17 GLOBAL MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	75
Nucleotide Receptor Drugs	75
P2Y Receptor Antagonists	75
Major Products	75
Market Revenue	76
<i>TABLE 29 GLOBAL MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	76
<i>FIGURE 18 GLOBAL MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 (\$ MILLIONS)</i>	77
SECRETIN-LIKE RECEPTOR DRUGS	77
Peptide Receptor Drugs	77
Amylin Receptor Agonists	77
Major Product	78
Market Revenue	78
<i>TABLE 30 GLOBAL MARKET FOR AMYLIN RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	78
<i>FIGURE 19 GLOBAL MARKET FOR AMYLIN RECEPTOR AGONIST, 2010-2018 (\$ MILLIONS)</i>	78
Glucagon-like Peptide (GLP) Receptor Agonists	79
Major Products	79
Other Products	79
GLPR Agonists in Development	80
<i>TABLE 31 GLP-1 RECEPTOR AGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET</i>	80
Market Revenue	80
<i>TABLE 32 GLOBAL MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	81

TOPIC	PAGE NO.
<i>FIGURE 20 GLOBAL MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 (\$ MILLIONS)</i>	81
Smoothened (SMO) Receptor Antagonists	81
Major Product	82
SMO Receptor Antagonists in Development	82
Market Revenue	82
<i>TABLE 33 GLOBAL MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	82
<i>FIGURE 21 GLOBAL MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	82
New Drug Classes in B-peptide Sub-class	83
Calcitonin Gene-related Peptide (CGRP) Receptor Antagonists	83
Frizzled Receptor Blockers	83
Hormone Receptor Drugs	84
Parathyroid Hormone (PTH) Receptor Agonists	84
Major Product	84
Other Product	84
Market Revenue	84
<i>TABLE 34 GLOBAL MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	85
<i>FIGURE 22 GLOBAL MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	85
METABOTROPIC GLUTAMATE/PHEROMONE RECEPTOR DRUGS	85
Proteinogenic Amino Acid Receptor Drugs	86
Metabotropic Glutamate Receptor Targeting Drugs	86
mGuR-targeting Drugs in Development	86
Ion Receptor Drugs	87
Calcium-sensing Receptor (CaSR) Agonists	87
Major Products	87
CaSR Agonists in Development	87
Market Revenue	87
<i>TABLE 35 GLOBAL MARKET FOR CALCIUM-SENSING RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	88
<i>FIGURE 23 GLOBAL MARKET FOR CALCIUM-SENSING RECEPTOR AGONISTS, 2010-2018 (\$ MILLIONS)</i>	88
MARKET ANALYSIS BY THERAPEUTIC APPLICATION	88
CARDIOVASCULAR DRUGS	89
<i>FIGURE 24 GLOBAL MARKET SHARE FOR GPCR CARDIOVASCULAR DRUGS, 2013 (%)</i>	89
<i>TABLE 36 GLOBAL MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	90
<i>FIGURE 25 GLOBAL MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)</i>	91
<i>FIGURE 26 REGIONAL MARKETS FOR GPCR CARDIOVASCULAR DRUGS, 2010-2018 (\$ MILLIONS)</i>	91
Anti-Hypertensives	92
Overview	93
Revenue	95
<i>FIGURE 27 GLOBAL MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)</i>	95

TOPIC	PAGE NO.
Platelet Aggregation Inhibitors	96
Overview	96
Revenue	97
<i>FIGURE 28 GLOBAL MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 (\$ MILLIONS)</i>	97
Other Anti-hypertensives	97
Overview	98
Revenue	99
<i>FIGURE 29 GLOBAL MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)</i>	99
CENTRAL NERVOUS SYSTEM (CNS) DRUGS	100
<i>FIGURE 30 GLOBAL MARKET SHARE FOR GPCR CNS DRUGS, 2013 (%)</i>	101
<i>TABLE 37 GLOBAL MARKET FOR GPCR CNS DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	102
<i>FIGURE 31 GLOBAL MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013 (%)</i>	103
<i>FIGURE 32 REGIONAL MARKETS FOR GPCR CNS DRUGS, 2010-2018 (\$ MILLIONS)</i>	103
Anti-Psychotics	104
Overview	105
Revenue	106
<i>FIGURE 33 GLOBAL MARKET FOR GPCR ANTI-PSYCHOTICS, 2010-2018 (\$ MILLIONS)</i>	106
Anti-Depressants	106
Overview	107
Revenue	107
<i>FIGURE 34 GLOBAL MARKET FOR GPCR ANTI-DEPPRESSANT DRUGS, 2010-2018 (\$ MILLIONS)</i>	107
Anti-Parkinson's Drugs	108
Overview	108
Revenue	109
<i>FIGURE 35 GLOBAL MARKET FOR GPCR ANTI-PARKINSON'S DRUGS, 2010-2018 (\$ MILLIONS)</i>	109
Anti-Migraine Drugs	109
Overview	110
Revenue	110
<i>FIGURE 36 GLOBAL MARKET FOR GPCR ANTI-MIGRAINE DRUGS, 2010-2018 (\$ MILLIONS)</i>	110
Nootropics	111
Overview	111
Revenue	111
<i>FIGURE 37 GLOBAL MARKET FOR GPCR NOOTROPIC DRUGS, 2010-2018 (\$ MILLIONS)</i>	111
Psychostimulants	112
Overview	112
Revenue	113
<i>FIGURE 38 GLOBAL MARKET FOR GPCR PSYCHOSTIMULANT DRUGS, 2010-2018 (\$ MILLIONS)</i>	113
Analgesics	113
Overview	113
Revenue	114
<i>FIGURE 39 GLOBAL MARKET FOR GPCR ANALGESIC DRUGS, 2010-2018 (\$ MILLIONS)</i>	114

TOPIC	PAGE NO.
Opioid Dependence Medications	114
Overview	115
Revenue	115
<i>FIGURE 40 GLOBAL MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 (\$ MILLIONS)</i>	115
RESPIRATORY DRUGS	115
<i>FIGURE 41 GLOBAL MARKET SHARE OF GPCR RESPIRATORY DRUGS, 2013 (%)</i>	116
<i>TABLE 38 GLOBAL MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	117
<i>FIGURE 42 GLOBAL MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013 (%)</i>	117
<i>FIGURE 43 REGIONAL MARKETS FOR GPCR RESPIRATORY DRUGS, 2010-2018 (\$ MILLIONS)</i>	119
Bronchodilators and Anti-Inflammatories	119
Overview	120
Revenue	121
<i>FIGURE 44 GLOBAL MARKET FOR GPCR BRONCHODILATORS, 2010-2018 (\$ MILLIONS)</i>	122
Anti-Allergics	122
Overview	122
Revenue	122
<i>FIGURE 45 GLOBAL MARKET FOR GPCR BRONCHODILATORS, 2010-2018 (\$ MILLIONS)</i>	123
IMMUNE SYSTEM	123
<i>FIGURE 46 GLOBAL MARKET SHARE FOR GPCR IMMUNOLOGY DRUGS, 2013</i>	123
<i>TABLE 39 GLOBAL MARKET FOR GPCR IMMUNOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	124
<i>FIGURE 47 GLOBAL MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013 (%)</i>	124
<i>FIGURE 48 REGIONAL MARKETS FOR THE GPCR IMMUNOLOGY DRUGS, 2010-2018 (\$ MILLIONS)</i>	125
Immunosuppressants	126
Overview	127
Revenue	127
<i>FIGURE 49 GLOBAL MARKET FOR GPCR IMMUNOSUPPRESSANTS, 2010-2018 (\$ MILLIONS)</i>	127
Anti-Retrovirals	128
Overview	128
Revenue	128
<i>FIGURE 50 GLOBAL MARKET FOR GPCR ANTI-RETROVIRALS, 2010-2018 (\$ MILLIONS)</i>	128
ENDOCRINOLOGY/METABOLIC DRUGS	129
<i>FIGURE 51 GLOBAL MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLIC DRUGS, 2013 (%)</i>	130
<i>TABLE 40 GLOBAL MARKET FOR GPCR ENDOCRINOLOGY/METABOLIC DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	131
<i>FIGURE 52 GLOBAL MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLIC DRUG COMPANIES, 2013 (%)</i>	131
<i>FIGURE 53 REGIONAL MARKETS FOR GPCR ENDOCRINOLOGY/METABOLIC DRUGS, 2010-2018 (\$ MILLIONS)</i>	132

TOPIC	PAGE NO.
Anti-Diabetics	132
Overview	133
Revenue	134
<i>FIGURE 54 GLOBAL MARKET FOR GPCR ANTI-DIABETICS, 2010-2018 (\$ MILLIONS)</i>	134
Infertility Treatments	134
Overview	134
Revenue	135
<i>FIGURE 55 GLOBAL MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 (\$ MILLIONS)</i>	135
Hormone Therapies	135
Overview	136
Revenue	137
<i>FIGURE 56 GLOBAL MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 (\$ MILLIONS)</i>	137
ONCOLOGY DRUGS	137
<i>FIGURE 57 GLOBAL MARKET SHARE OF GPCR ONCOLOGY DRUGS, 2013</i>	138
<i>TABLE 41 GLOBAL MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	138
<i>FIGURE 58 GLOBAL MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013 (\$ MILLIONS)</i>	139
<i>FIGURE 59 REGIONAL MARKET FOR GPCR ONCOLOGY DRUGS, 2010-2018 (\$ MILLIONS)</i>	140
Anti-Neoplastic Drugs	140
Overview	141
Revenue	142
<i>FIGURE 60 GLOBAL MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 (\$ MILLIONS)</i>	142
Anti-Emetics	142
Overview	143
Revenue	143
<i>FIGURE 61 GLOBAL MARKET FOR GPCR ANTI-EMETICS, 2010-2018 (\$ MILLIONS)</i>	143
Hematopoietic Stem Cell Mobilizers (HSCMs)	143
Overview	144
Revenue	144
<i>FIGURE 62 GLOBAL MARKET FOR GPCR HEMATOPOIETIC STEM CELL MOBILIZERS, 2010-2018 (\$ MILLIONS)</i>	144
GENITOURINARY DRUGS	144
<i>FIGURE 63 GLOBAL MARKET SHARE OF GPCR GENITOURINARY DRUGS, 2013 (%)</i>	145
<i>TABLE 42 GLOBAL MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	146
<i>FIGURE 64 GLOBAL MARKET SHARE OF GPCR GENITOURINARY DRUG COMPANIES, 2013 (%)</i>	146
<i>FIGURE 65 REGIONAL MARKET FOR GPCR GENITOURINARY DRUGS, 2010-2018 (\$ MILLIONS)</i>	146
Anti-Diuretics	147
Overview	148
Revenue	148
<i>FIGURE 66 GLOBAL MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 (\$ MILLIONS)</i>	148
Diuretics	149

TOPIC	PAGE NO.
Overview	149
Revenue	149
<i>FIGURE 67 GLOBAL MARKET FOR GPCR DIURETICS, 2010-2018 (\$ MILLIONS)</i>	149
OPHTHALMICS	150
<i>TABLE 43 GLOBAL MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	151
<i>FIGURE 68 GLOBAL MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013 (%)</i>	151
<i>FIGURE 69 REGIONAL MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 (\$ MILLIONS)</i>	152
Anti-Glaucoma Drugs	153
Overview	153
Revenue	153
<i>FIGURE 70 GLOBAL MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 (\$ MILLIONS)</i>	153
CHAPTER 6 MARKETS IN THE UNITED STATES	155
MARKET ANALYSIS	155
<i>TABLE 44 U.S. MARKET FOR GPCR DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	155
<i>FIGURE 71 U.S. MARKET FOR GPCR DRUGS, 2010-2018 (\$ MILLIONS)</i>	156
RHODOPSIN-LIKE RECEPTOR DRUGS	156
Peptide Receptor Drugs	156
Angiotensin II Receptor Antagonists	156
Overview	157
Revenue	157
<i>TABLE 45 U.S. MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBs), THROUGH 2018 (\$ MILLIONS)</i>	157
<i>FIGURE 72 U.S. MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBs), 2010-2018 (\$ MILLIONS)</i>	157
Bradykinin Receptor Antagonists	158
Overview	158
Revenue	158
<i>TABLE 46 U.S. MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	159
<i>FIGURE 73 U.S. MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	159
Opioid Receptor Targeting Drugs	159
Overview	160
Revenue	160
<i>TABLE 47 U.S. MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	161
<i>FIGURE 74 U.S. MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	161
Chemokine Receptor Antagonists	161
Overview	162
Revenue	162
<i>TABLE 48 U.S. MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	162
<i>FIGURE 75 U.S. MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	162

TOPIC	PAGE NO.
Somatostatin Receptor Agonists	163
Overview	163
Revenue	164
<i>TABLE 49 U.S. MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 (\$ MILLIONS)</i>	164
<i>FIGURE 76 U.S. MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 (\$ MILLIONS)</i>	164
Neurokinin Receptor Antagonists	164
Overview	165
Revenue	165
<i>TABLE 50 U.S. MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	165
<i>FIGURE 77 U.S. MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	165
Vasopressin Receptor Antagonists	166
Overview	166
Revenue	166
<i>TABLE 51 U.S. MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	166
<i>FIGURE 78 U.S. MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	166
Endothelin Receptor Antagonists	167
Overview	167
Revenue	168
<i>TABLE 52 U.S. MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	168
<i>FIGURE 79 U.S. MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	168
Biogenic Amine Receptor Drugs	169
Muscarinic Receptor Targeting Drugs	169
Overview	169
Revenue	169
<i>TABLE 53 U.S. MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	170
<i>FIGURE 80 U.S. MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	170
Adrenergic Receptor Targeting Drugs	170
Overview	170
Revenue	171
<i>TABLE 54 U.S. MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	171
<i>FIGURE 81 U.S. MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	172
Dopamine Receptor Drugs	172
Overview	173
Revenue	173
<i>TABLE 55 U.S. MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	174
<i>FIGURE 82 U.S. MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	174
Histamine Receptor Antagonists	174

TOPIC	PAGE NO.
Overview	175
Revenue	175
<i>TABLE 56 U.S. MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	175
<i>FIGURE 83 U.S. MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	175
Serotonin Receptor Targeting Drugs	176
Overview	176
Revenue	177
<i>TABLE 57 U.S. MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	177
<i>FIGURE 84 U.S. MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	178
Hormone Receptor Drugs	178
FSH, LH and GNRH Receptor Drugs	178
Overview	179
Revenue	179
<i>TABLE 58 U.S. MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	179
<i>FIGURE 85 U.S. MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	179
Lipid and Phospholipid Receptor Drugs	180
Eicosanoid Receptor Drugs	180
Overview	180
Revenue	181
<i>TABLE 59 U.S. MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	181
<i>FIGURE 86 U.S. MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	181
S1P Receptor Modulators	182
Overview	182
Revenue	182
<i>TABLE 60 U.S. MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	183
<i>FIGURE 87 U.S. MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	183
Nucleotide Receptor Drugs	183
P2Y Receptor Antagonists	183
Overview	184
Revenue	184
<i>TABLE 61 U.S. MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	184
<i>FIGURE 88 U.S. MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 (\$ MILLIONS)</i>	184
SECRETIN RECEPTOR DRUGS	185
Peptide Receptor Drugs	185
Amylin Receptor Agonists	185
Overview	186
Revenue	186

TOPIC	PAGE NO.
<i>TABLE 62 U.S. MARKET FOR MARKET FOR AMYLIN RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	186
<i>FIGURE 89 U.S. MARKET FOR MARKET FOR AMYLIN RECEPTOR AGONISTS, 2010-2018 (\$ MILLIONS)</i>	186
Glucagon-like Peptide (GLP) Receptor Agonists	187
Overview	187
Revenue	187
<i>TABLE 63 U.S. MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	188
<i>FIGURE 90 U.S. MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 (\$ MILLIONS)</i>	188
Smoothened (SMO) Receptor Antagonists	188
Overview	189
Revenue	189
<i>TABLE 64 U.S. MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	189
<i>FIGURE 91 U.S. MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	189
Hormone Receptor Drugs	190
Parathyroid Hormone (PTH) Receptor Agonists	190
Overview	190
Revenue	190
<i>TABLE 65 U.S. MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	190
<i>FIGURE 92 U.S. MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	191
METABOTROPIC GLUTAMATE RECEPTOR DRUGS	191
Calcium-sensing Receptor (CaSR) Agonists	191
Overview	191
Revenue	191
<i>TABLE 66 U.S. MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, THROUGH 2018 (\$ MILLIONS)</i>	192
<i>FIGURE 93 U.S. MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, 2010-2018 (\$ MILLIONS)</i>	192
MARKET ANALYSIS BY THERAPEUTIC APPLICATION	192
CARDIOVASCULAR DRUGS	193
<i>TABLE 67 U.S. MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	193
<i>FIGURE 94 U.S. MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)</i>	193
Anti-Hypertensives	194
Overview	194
Revenue	195
<i>FIGURE 95 U.S. MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)</i>	196
Platelet Aggregation Inhibitors	196
Overview	196
Revenue	197
<i>FIGURE 96 U.S. MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 (\$ MILLIONS)</i>	197
Other Anti-Hypertensives	197

TOPIC	PAGE NO.
Overview	197
Revenue	198
<i>FIGURE 97 U.S. MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)</i>	198
CENTRAL NERVOUS SYSTEM (CNS) DRUGS	198
<i>TABLE 68 U.S. MARKET FOR GPCR CNS DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	199
<i>FIGURE 98 U.S. MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013</i>	199
Anti-Psychotics	200
Overview	200
Revenue	201
<i>FIGURE 99 U.S. MARKET FOR GPCR GPCR ANTI-PSYCHOTICS, 2010-2018 (\$ MILLIONS)</i>	201
Anti-Depressants	201
Overview	202
Revenue	202
<i>FIGURE 100 U.S. MARKET FOR GPCR ANTI-DEPRESSANTS, 2010-2018 (\$ MILLIONS)</i>	202
Anti-Parkinson's Drugs	203
Overview	203
Revenue	203
<i>FIGURE 101 U.S. MARKET FOR GPCR ANTI-PARKINSON'S DRUGS, 2010-2018 (\$ MILLIONS)</i>	203
Anti-Migraine Drugs	204
Overview	204
Revenue	205
<i>FIGURE 102 U.S. MARKET FOR GPCR ANTI-MIGRAINE DRUGS, 2010-2018 (\$ MILLIONS)</i>	205
Nootropics	205
Overview	206
Revenue	206
<i>FIGURE 103 U.S. MARKET FOR GPCR NOOTROPICS, 2010-2018 (\$ MILLIONS)</i>	206
Psychostimulants	206
Overview	207
Revenue	207
<i>FIGURE 104 U.S. MARKET FOR PSYCHOSTIMULANTS, 2010-2018 (\$ MILLIONS)</i>	207
Analgesics	207
Overview	208
Revenue	208
<i>FIGURE 105 U.S. MARKET FOR ANALGESICS, 2010-2018 (\$ MILLIONS)</i>	208
Opioid Dependence Medications	208
Overview	209
Revenue	209
<i>FIGURE 106 U.S. MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 (\$ MILLIONS)</i>	209
RESPIRATORY DRUGS	210
<i>TABLE 69 U.S. MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	210
<i>FIGURE 107 U.S. MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013 (%)</i>	210
Bronchodilators and Anti-Inflammatories	211

TOPIC	PAGE NO.
Overview	212
Revenue	212
<i>FIGURE 108 U.S. MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 (\$ MILLIONS)</i>	213
Anti-Allergics	213
Overview	214
Revenue	214
<i>FIGURE 109 U.S. MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 (\$ MILLIONS)</i>	214
IMMUNOLOGY DRUGS	214
<i>TABLE 70 U.S. MARKET FOR GPCR IMMUNOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	215
<i>FIGURE 110 U.S. MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013 (%)</i>	215
Immunosuppressants	216
Overview	216
Revenue	216
<i>FIGURE 111 U.S. MARKET FOR GPCR IMMUNOSUPPRESSANTS, 2010-2018 (\$ MILLIONS)</i>	216
Anti-Retrovirals	217
Overview	217
Revenue	217
<i>FIGURE 112 U.S. MARKET FOR GPCR ANTI-RETROVIRALS, 2010-2018 (\$ MILLIONS)</i>	217
ENDOCRINOLOGY/METABOLIC DRUGS	218
<i>TABLE 71 U.S. MARKET FOR GPCR ENDOCRINOLOGY/METABOLIC DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	218
<i>FIGURE 113 U.S. MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, 2013</i>	219
Anti-Diabetics	219
Overview	220
Revenue	220
<i>FIGURE 114 U.S. MARKET FOR GPCR ANTI-DIABETICS, 2010-2018 (\$ MILLIONS)</i>	220
Infertility Treatments	221
Overview	221
Revenue	221
<i>FIGURE 115 U.S. MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 (\$ MILLIONS)</i>	221
Hormone Therapies	222
Overview	222
Revenue	223
<i>FIGURE 116 U.S. MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 (\$ MILLIONS)</i>	224
ONCOLOGY DRUGS	224
<i>TABLE 72 U.S. MARKET FOR ONCOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	224
<i>FIGURE 117 U.S. MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, THROUGH 2018 (%)</i>	225
Anti-Neoplastic Agents	225
Overview	226
Revenue	226
<i>FIGURE 118 U.S. MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 (\$ MILLIONS)</i>	227

TOPIC	PAGE NO.
Anti-Emetics	227
Overview	227
Revenue	227
<i>FIGURE 119 U.S. MARKET FOR GPCR ANTI-EMETICS, 2010-2018 (\$ MILLIONS)</i>	227
Hematopoietic Stem Cell Mobilizers (HSCMs)	228
Overview	228
Revenue	228
<i>FIGURE 120 U.S. MARKET FOR GPCR HSCMS, 2010-2018 (\$ MILLIONS)</i>	228
GENITOURINARY DRUGS	229
<i>TABLE 73 U.S. MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	229
<i>FIGURE 121 U.S. MARKET SHARE OF GPCR GENITOURINARY DRUG COMPANIES, 2013 (%)</i>	229
Anti-Diuretics	230
Overview	230
Revenue	231
<i>FIGURE 122 U.S. MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 (\$ MILLIONS)</i>	231
Diuretics	232
Overview	232
Revenue	232
<i>FIGURE 123 U.S. MARKET FOR GPCR DIURETICS, 2010-2018 (\$ MILLIONS)</i>	233
OPHTHALMIC DRUGS	233
Anti-Glaucoma Drugs	233
Overview	233
Revenue	234
<i>TABLE 74 U.S. MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	234
<i>FIGURE 124 U.S. MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 (\$ MILLIONS)</i>	234
<i>FIGURE 125 U.S. MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013 (%)</i>	234
CHAPTER 7 MARKETS IN THE EUROPEAN UNION	237
MARKET ANALYSIS	237
<i>TABLE 75 EU MARKET FOR GPCR DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	237
<i>FIGURE 126 EU MARKET FOR GPCR DRUGS, 2010-2018 (\$ MILLIONS)</i>	237
RHODOPSIN-LIKE RECEPTOR DRUGS	238
Peptide Receptor Drugs	238
Angiotensin II Receptor Antagonists	238
Overview	239
Revenue	239
<i>TABLE 76 EU MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), THROUGH 2018 (\$ MILLIONS)</i>	239
<i>FIGURE 127 EU MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), 2010-2018 (\$ MILLIONS)</i>	239
Bradykinin Receptor Antagonists	240
Overview	240
Revenue	240
<i>TABLE 77 EU MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	241

TOPIC	PAGE NO.
<i>FIGURE 128 EU MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	241
Opioid Receptor Targeting Drugs	241
Overview	242
Revenue	242
<i>TABLE 78 EU MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	242
<i>FIGURE 129 EU MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	242
Chemokine Receptor Antagonists	243
Overview	243
Revenue	244
<i>TABLE 79 EU MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	244
<i>FIGURE 130 EU MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	244
Somatostatin Receptor Agonists	244
Overview	245
Revenue	245
<i>TABLE 80 EU MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 (\$ MILLIONS)</i>	245
<i>FIGURE 131 EU MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 (\$ MILLIONS)</i>	245
Neurokinin Receptor Antagonists	246
Overview	246
Revenue	246
<i>TABLE 81 EU MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	246
<i>FIGURE 132 EU MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	247
Vasopressin Receptor Antagonists	247
Overview	247
Revenue	247
<i>TABLE 82 EU MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	248
<i>FIGURE 133 EU MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	248
Endothelin Receptor Antagonists	248
Overview	248
Revenue	249
<i>TABLE 83 EU MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	249
<i>FIGURE 134 EU MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	249
Biogenic Amine Receptor Drugs	250
Muscarinic Receptor Targeting Drugs	250
Overview	250
Revenue	250
<i>TABLE 84 EU MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	250

TOPIC	PAGE NO.
<i>FIGURE 135 EU MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	250
Adrenergic Receptor Targeting Drugs	251
Overview	251
Revenue	252
<i>TABLE 85 EU MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	252
<i>FIGURE 136 EU MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	252
Dopamine Receptor Drugs	253
Overview	253
Revenue	254
<i>TABLE 86 EU MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	254
<i>FIGURE 137 EU MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	254
Histamine Receptor Antagonists	255
Overview	255
Revenue	255
<i>TABLE 87 EU MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	256
<i>FIGURE 138 EU MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	256
Serotonin Receptor Targeting Drugs	256
Overview	256
Revenue	257
<i>TABLE 88 EU MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	257
<i>FIGURE 139 EU MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	258
Hormone Receptor Drugs	258
FSH, LH AND GNRH Receptor Drugs	258
Overview	259
Revenue	259
<i>TABLE 89 EU MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	259
<i>FIGURE 140 EU MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	259
Lipid and Phospholipid Receptor Drugs	260
Eicosanoid Receptor Drugs	260
Overview	260
Revenue	261
<i>TABLE 90 EU MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	261
<i>FIGURE 141 EU MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	261
S1P Receptor Modulators	262
Overview	262
Revenue	262

TOPIC	PAGE NO.
<i>TABLE 91 EU MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	262
<i>FIGURE 142 EU MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	263
Nucleotide Receptor Drugs	263
P2Y Receptor Antagonists	263
Overview	263
Revenue	264
<i>TABLE 92 EU MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	264
<i>FIGURE 143 EU MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 (\$ MILLIONS)</i>	264
SECRETIN-LIKE RECEPTOR DRUGS	265
Peptide Receptor Drugs	265
Glucagon-like Peptide (GLP) Receptor Agonists	265
Overview	265
Revenue	265
<i>TABLE 93 EU MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	266
<i>FIGURE 144 EU MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 (\$ MILLIONS)</i>	266
Smoothened (SMO) Receptor Antagonists	266
Overview	267
Revenue	267
<i>TABLE 94 EU MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	267
<i>FIGURE 145 EU MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	267
Hormone Receptor Drugs	268
Parathyroid Hormone (PTH) Receptor Agonists	268
Overview	268
Revenue	268
<i>TABLE 95 EU MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	268
<i>FIGURE 146 EU MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	268
METABOTROPIC GLUTAMATE-LIKE RECEPTOR DRUGS	269
Ion Receptor Drugs	269
Calcium-Sensing Receptor (CaSR) Agonists	269
Overview	269
Revenue	270
<i>TABLE 96 EU MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, THROUGH 2018 (\$ MILLIONS)</i>	270
<i>FIGURE 147 EU MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, 2010-2018 (\$ MILLIONS)</i>	270
MARKET ANALYSIS BY THERAPEUTIC APPLICATION	270
CARDIOVASCULAR DRUGS	271
<i>TABLE 97 EU MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	271

TOPIC	PAGE NO.
<i>FIGURE 148 EU MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)</i>	271
Anti-Hypertensives	272
Overview	272
Revenue	273
<i>FIGURE 149 EU MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)</i>	273
Platelet Aggregation Inhibitors	273
Overview	274
Revenue	274
<i>FIGURE 150 EU MARKET FOR gpcr PLATELET AGGREGATION INHIBITORS, 2010-2018 (\$ MILLIONS)</i>	274
Other Anti-Hypertensives	275
Overview	275
Revenue	275
<i>FIGURE 151 EU MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)</i>	276
CENTRAL NERVOUS SYSTEM (CNS) DRUGS	276
<i>TABLE 98 EU MARKET FOR GPCR CNS DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	276
<i>FIGURE 152 EU MARKET SHARE OF CNS DRUG COMPANIES, 2013 (%)</i>	277
Anti-Psychotics	277
Overview	278
Revenue	278
<i>FIGURE 153 EU MARKET FOR GPCR ANTI-PSYCHOTICS, 2010-2018 (\$ MILLIONS)</i>	278
Anti-Parkinson's Drugs	279
Overview	279
Revenue	279
<i>FIGURE 154 EU MARKET FOR GPCR ANTI-PARKINSON'S, 2010-2018 (\$ MILLIONS)</i>	279
Anti-Migraine Drugs	280
Overview	280
Revenue	281
<i>FIGURE 155 EU MARKET FOR GPCR ANTI-MIGRAINE DRUGS, 2010-2018 (\$ MILLIONS)</i>	281
Nootropics	281
Overview	281
Revenue	282
<i>FIGURE 156 EU MARKET FOR GPCR NOOTROPICS, 2010-2018 (\$ MILLIONS)</i>	282
Psychostimulants	282
Overview	282
Revenue	283
<i>FIGURE 157 EU MARKET FOR GPCR PSYCHOSTIMULANTS, 2010-2018 (\$ MILLIONS)</i>	283
Analgesics	283
Overview	283
Revenue	284
<i>FIGURE 158 EU MARKET FOR GPCR ANALGESICS, 2010-2018 (\$ MILLIONS)</i>	284
Opioid Dependence Medications	284
Overview	284
Revenue	285

TOPIC	PAGE NO.
<i>FIGURE 159 EU MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 (\$ MILLIONS)</i>	285
RESPIRATORY DRUGS	285
<i>TABLE 99 EU MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	285
<i>FIGURE 160 EU MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013</i>	286
Bronchodilators and Anti-inflammatories	286
Overview	287
Revenue	287
<i>FIGURE 161 EU MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 (\$ MILLIONS)</i>	287
Anti-Allergics	288
Overview	288
Revenue	288
<i>FIGURE 162 EU MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 (\$ MILLIONS)</i>	288
IMMUNOLOGY DRUGS	289
<i>TABLE 100 EU MARKET FOR GPCR IMMUNOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	289
<i>FIGURE 163 EU MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013 (\$ MILLIONS)</i>	289
Immunosuppressants	290
Overview	290
Revenue	291
<i>FIGURE 164 EU MARKET FOR GPCR IMMUNOSUPPRESSANTS, 2010-2018 (\$ MILLIONS)</i>	291
Anti-Retrovirals	291
Overview	292
Revenue	292
<i>FIGURE 165 EU MARKET FOR GPCR ANTI-RETROVIRALS, 2010-2018 (\$ MILLIONS)</i>	292
ENDOCRINOLOGY/METABOLIC DRUGS	292
<i>TABLE 101 EU MARKET FOR GPCR ENDOCRINOLOGY/METABOLIC DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	293
<i>FIGURE 166 EU MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, 2013</i>	293
Anti-Diabetics	294
Overview	294
Revenue	294
<i>FIGURE 167 EU MARKET FOR GPCR ANTI-DIABETICS, 2010-2018 (\$ MILLIONS)</i>	294
Infertility Treatments	295
Overview	295
Revenue	295
<i>FIGURE 168 EU MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 (\$ MILLIONS)</i>	295
Hormone Therapies	296
Overview	297
Revenue	297
<i>FIGURE 169 EU MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 (\$ MILLIONS)</i>	297
ONCOLOGY DRUGS	298

TOPIC	PAGE NO.
<i>TABLE 102 EU MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	298
<i>FIGURE 170 EU MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013</i>	298
Anti-Neoplastic Agents	299
Overview	299
Revenue	300
<i>FIGURE 171 EU MARKET FOR GPCR ANTI-NEOPLASTIC AGENTS, 2010-2018 (\$ MILLIONS)</i>	300
Anti-Emetics	300
Overview	301
Revenue	301
<i>FIGURE 172 EU MARKET FOR GPCR ANTI-EMETICS, 2010-2018 (\$ MILLIONS)</i>	301
Hematopoietic Stem Cell Mobilizers	301
Overview	302
Revenue	302
<i>FIGURE 173 EU MARKET FOR GPCR HSCMS, 2010-2018 (\$ MILLIONS)</i>	302
GENITOURINARY DRUGS	302
<i>TABLE 103 EU MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	303
<i>FIGURE 174 EU MARKET SHARE OF GPCR GENITOURINARY DRUG COMPANIES, 2013 (%)</i>	303
Anti-Diuretics	304
Overview	304
Revenue	304
<i>FIGURE 175 EU MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 (\$ MILLIONS)</i>	304
Diuretics	305
Overview	305
Revenue	305
<i>FIGURE 176 EU MARKET FOR GPCR DIURETICS, 2010-2018 (\$ MILLIONS)</i>	305
OPHTHALMIC DRUGS	306
Anti-Glaucoma Drugs	306
Overview	306
Revenue	307
<i>TABLE 104 EU MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	307
<i>FIGURE 177 EU MARKET FOR GPCR ANTI-GLAUCOMA AGENTS, 2010-2018 (\$ MILLIONS)</i>	307
<i>FIGURE 178 EU MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013</i>	307
CHAPTER 8 MARKETS IN JAPAN	310
MARKET ANALYSIS	310
<i>TABLE 105 JAPAN MARKET FOR GPCR DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	310
<i>FIGURE 179 JAPAN MARKET FOR GPCR DRUGS, 2010-2018 (\$ MILLIONS)</i>	310
RHODOPSIN-LIKE RECEPTOR DRUGS	311
Peptide Receptor Drugs	311
Angiotensin II Receptor Antagonists	311
Overview	312
Revenue	312

TOPIC	PAGE NO.
<i>TABLE 106 JAPAN MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), THROUGH 2018 (\$ MILLIONS)</i>	312
<i>FIGURE 180 JAPAN MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), 2010-2018 (\$ MILLIONS)</i>	312
Opioid Receptor Targeting Drugs	313
Overview	313
Revenue	314
<i>TABLE 107 JAPAN MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	314
<i>FIGURE 181 JAPAN MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	314
Chemokine Receptor Antagonists	315
Overview	315
Revenue	315
<i>TABLE 108 JAPAN MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	315
<i>FIGURE 182 JAPAN MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	316
Somatostatin Receptor Agonists	316
Overview	316
Revenue	316
<i>TABLE 109 JAPAN MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 (\$ MILLIONS)</i>	316
<i>FIGURE 183 JAPAN MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 (\$ MILLIONS)</i>	317
Neurokinin Receptor Antagonists	317
Overview	317
Revenue	318
<i>TABLE 110 JAPAN MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	318
<i>FIGURE 184 JAPAN MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	318
Vasopressin Receptor Antagonists	318
Overview	319
Revenue	319
<i>TABLE 111 JAPAN MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	319
<i>FIGURE 185 JAPAN MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	319
Endothelin Receptor Antagonists	319
Overview	320
Revenue	320
<i>TABLE 112 JAPAN MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	320
<i>FIGURE 186 JAPAN MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	321
Biogenic Amine Receptor Drugs	321
Muscarinic Receptor Targeting Drugs	321
Overview	321
Revenue	321

TOPIC	PAGE NO.
<i>TABLE 113 JAPAN MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	322
<i>FIGURE 187 JAPAN MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	322
Adrenergic Receptor Targeting Drugs	322
Overview	322
Revenue	323
<i>TABLE 114 JAPAN MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	323
<i>FIGURE 188 JAPAN MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	324
Dopamine Receptor Drugs	324
Overview	324
Revenue	325
<i>TABLE 115 JAPAN MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	325
<i>FIGURE 189 JAPAN MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	325
Histamine Receptor Antagonists	325
Overview	326
Revenue	326
<i>TABLE 116 JAPAN MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	326
<i>FIGURE 190 JAPAN MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	326
Serotonin Receptor Targeting Drugs	327
Overview	327
Revenue	327
<i>TABLE 117 JAPAN MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	327
<i>FIGURE 191 JAPAN MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	327
Hormone Receptor Drugs	328
FSH, LH AND GNRH Receptor Drugs	328
Overview	328
Revenue	329
<i>TABLE 118 JAPAN MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	329
<i>FIGURE 192 JAPAN MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	329
Lipid and Phospholipid Receptor Drugs	330
Eicosanoid Receptor Drugs	330
Overview	330
Revenue	330
<i>TABLE 119 JAPAN MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	330
<i>FIGURE 193 JAPAN MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	330
S1P Receptor Modulators	331
Overview	331

TOPIC	PAGE NO.
Revenue	331
<i>TABLE 120 JAPAN MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	332
<i>FIGURE 194 JAPAN MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	332
Nucleotide Receptor Drugs	332
P2Y Receptor Antagonists	332
Overview	333
Revenue	333
<i>TABLE 121 JAPAN MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	333
<i>FIGURE 195 JAPAN MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 (\$ MILLIONS)</i>	333
SECRETIN-LIKE RECEPTOR DRUGS	334
Peptide Receptor Drugs	334
Glucagon-like peptide (GLP) Receptor Agonists	334
Overview	334
Revenue	334
<i>TABLE 122 JAPAN MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	335
<i>FIGURE 196 JAPAN MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 (\$ MILLIONS)</i>	335
Smoothened (SMO) Receptor Antagonists	335
Hormone Receptor Drugs	335
Parathyroid Hormone (PTH) Receptor Agonists	335
Overview	336
Revenue	336
<i>TABLE 123 JAPAN MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	336
<i>FIGURE 197 JAPAN MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	336
METABOTROPIC GLUTAMATE-LIKE RECEPTOR DRUGS	336
Ion Receptor Drugs	337
Calcium-Sensing Receptor (CaSR) Agonists	337
Overview	337
Revenue	337
<i>TABLE 124 JAPAN MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, THROUGH 2018 (\$ MILLIONS)</i>	337
<i>FIGURE 198 JAPAN MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, 2010-2018 (\$ MILLIONS)</i>	338
JAPANESE MARKET ANALYSIS BY THERAPEUTIC APPLICATION	338
CARDIOVASCULAR DRUGS	338
<i>TABLE 125 JAPAN MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	339
<i>FIGURE 199 JAPAN MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013</i>	339
Anti-Hypertensives	340
Overview	340
Revenue	340

TOPIC	PAGE NO.
<i>FIGURE 200 JAPAN MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)</i>	340
Platelet Aggregation Inhibitors	341
Overview	341
Revenue	341
<i>FIGURE 201 JAPAN MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 (\$ MILLIONS)</i>	341
Other Anti-Hypertensives	342
Overview	342
Revenue	342
<i>FIGURE 202 JAPAN MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)</i>	342
CENTRAL NERVOUS SYSTEM (CNS) DRUGS	343
<i>TABLE 126 JAPAN MARKET FOR GPCR CNS DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	343
<i>FIGURE 203 JAPAN MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013</i>	344
Anti-Psychotics	344
Overview	345
Revenue	345
<i>FIGURE 204 JAPAN MARKET FOR GPCR ANTI-PSYCHOTICS, 2010-2018 (\$ MILLIONS)</i>	345
Anti-Parkinson's Drugs	345
Overview	346
Revenue	346
<i>FIGURE 205 JAPAN MARKET FOR GPCR ANTI-PARKINSON'S, 2010-2018 (\$ MILLIONS)</i>	346
Anti-Migraine Drugs	346
Overview	347
Revenue	347
<i>FIGURE 206 JAPAN MARKET FOR GPCR ANTI-MIGRAINE, 2010-2018 (\$ MILLIONS)</i>	347
Nootropics	347
Overview	348
Revenue	348
<i>FIGURE 207 JAPAN MARKET FOR GPCR NOOTROPICS, THROUGH 2018 (\$ MILLIONS)</i>	348
Psychostimulants	348
Overview	348
Revenue	349
<i>FIGURE 208 JAPAN MARKET FOR PSYCHOSTIMULANTS, 2010-2018 (\$ MILLIONS)</i>	349
Analgesics	349
Overview	349
Revenue	350
<i>FIGURE 209 JAPAN MARKET FOR GPCR ANALGESICS, 2010-2018 (\$ MILLIONS)</i>	350
Opioid Dependence Medications	350
Overview	350
Revenue	350
<i>FIGURE 210 JAPAN MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 (\$ MILLIONS)</i>	350
RESPIRATORY DRUGS	351
<i>TABLE 127 JAPAN MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	351
<i>FIGURE 211 JAPAN MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013</i>	351

TOPIC	PAGE NO.
Bronchodilators and Anti-Inflammatories	352
Overview	353
Revenue	353
<i>FIGURE 212 JAPAN MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 (\$ MILLIONS)</i>	353
Anti-Allergics	354
Overview	354
Revenue	354
<i>FIGURE 213 JAPAN MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 (\$ MILLIONS)</i>	354
IMMUNOLOGY DRUGS	355
<i>TABLE 128 JAPAN MARKET FOR IMMUNOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	355
<i>FIGURE 214 JAPAN MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013</i>	355
Immunosuppressants	356
Overview	356
Revenue	356
<i>FIGURE 215 JAPAN MARKET FOR IMMUNOSUPPRESSANTS, 2010-2018 (\$ MILLIONS)</i>	357
Anti-Retrovirals	357
Overview	357
Revenue	357
<i>FIGURE 216 JAPAN MARKET FOR GPCR ANTI-RETROVIRALS, 2010-2018 (\$ MILLIONS)</i>	357
ENDOCRINOLOGY/METABOLIC DRUGS	358
<i>TABLE 129 JAPAN MARKET FOR GPCR ENDOCRINOLOGY/METABOLICS DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	358
<i>FIGURE 217 JAPAN MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, 2013</i>	359
Anti-Diabetics	359
Overview	360
Revenue	360
<i>FIGURE 218 JAPAN GPCR ANTI-DIABETICS, 2010-2018 (\$ MILLIONS)</i>	360
Infertility Treatments	360
Overview	360
Revenue	361
<i>FIGURE 219 JAPAN GPCR INFERTILITY TREATMENTS, 2010-2018 (\$ MILLIONS)</i>	361
Hormone Therapies	361
Overview	362
Revenue	362
<i>FIGURE 220 JAPAN MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 (\$ MILLIONS)</i>	362
ONCOLOGY DRUGS	363
<i>TABLE 130 JAPAN MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	363
<i>FIGURE 221 JAPAN MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013</i>	363
Anti-Neoplastic Agents	364
Overview	364
Revenue	364
<i>FIGURE 222 JAPAN MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 (\$ MILLIONS)</i>	364
Anti-Emetics	365

TOPIC	PAGE NO.
Overview	365
Revenue	365
<i>FIGURE 223 JAPAN MARKET FOR GPCR ANTI-EMETICS, 2010-2018 (\$ MILLIONS)</i>	365
GENITOURINARY DRUGS	366
<i>TABLE 131 JAPAN MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	366
<i>FIGURE 224 JAPAN MARKET SHARE OF GPCR GENITOURINARY DRUG COMPANIES, 2013 (\$ MILLIONS)</i>	366
Anti-Diuretics	367
Overview	367
Revenue	368
<i>FIGURE 225 JAPAN MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 (\$ MILLIONS)</i>	368
Diuretics	368
Overview	368
Revenue	368
<i>FIGURE 226 JAPAN MARKET FOR GPCR DIURETICS, 2010-2018 (\$ MILLIONS)</i>	369
OPHTHALMIC DRUGS	369
Anti-Glaucoma Drugs	369
Overview	369
Revenue	369
<i>TABLE 132 JAPAN MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	370
<i>FIGURE 227 JAPAN MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 (\$ MILLIONS)</i>	370
<i>FIGURE 228 JAPAN MARKET SHARE OF OPHTHALMIC DRUG COMPANIES, THROUGH 2018</i>	370
CHAPTER 9 MARKETS IN BRIC	373
MARKET ANALYSIS	373
<i>TABLE 133 BRIC MARKET FOR GPCR DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	373
<i>FIGURE 229 BRIC MARKET FOR GPCR DRUGS, 2010-2018 (\$ MILLIONS)</i>	373
RHODOPSIN-LIKE RECEPTOR DRUGS	374
Peptide Receptor Drugs	375
Angiotensin II Receptor Antagonists	375
Overview	375
Revenue	375
<i>TABLE 134 BRIC MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBs), THROUGH 2018 (\$ MILLIONS)</i>	375
<i>FIGURE 230 BRIC MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBs), 2010-2018 (\$ MILLIONS)</i>	375
Bradykinin Receptor Antagonists	376
Overview	376
Revenue	376
<i>TABLE 135 BRIC MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	377
<i>FIGURE 231 BRIC MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	377
Opioid Receptor Targeting Drugs	377
Overview	378

TOPIC	PAGE NO.
Revenue	378
<i>TABLE 136 BRIC MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	378
<i>FIGURE 232 BRIC MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	378
Chemokine Receptor Antagonists	379
Overview	379
Revenue	379
<i>TABLE 137 BRIC MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	380
<i>FIGURE 233 BRIC MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	380
Somatostatin Receptor Agonists	380
Overview	380
Revenue	381
<i>TABLE 138 BRIC MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 (\$ MILLIONS)</i>	381
<i>FIGURE 234 BRIC MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 (\$ MILLIONS)</i>	381
Endothelin Receptor Antagonists	381
Overview	382
Revenue	382
<i>TABLE 139 BRIC MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	382
<i>FIGURE 235 BRIC MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	383
Biogenic Amine Receptor Drugs	383
Muscarinic Receptor Targeting Drugs	383
Overview	383
Revenue	383
<i>TABLE 140 BRIC MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	384
<i>FIGURE 236 BRIC MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	384
Adrenergic Receptor Targeting Drugs	384
Overview	385
Revenue	385
<i>TABLE 141 BRIC MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	385
<i>FIGURE 237 BRIC MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	385
Dopamine Receptor Drugs	386
Overview	386
Revenue	387
<i>TABLE 142 BRIC MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	387
<i>FIGURE 238 BRIC MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	387
Histamine Receptor Antagonists	388
Overview	388

TOPIC	PAGE NO.
Revenue	388
<i>TABLE 143 BRIC MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	388
<i>FIGURE 239 BRIC MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	388
Serotonin Receptor Targeting Drugs	389
Overview	389
Revenue	389
<i>TABLE 144 BRIC MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	389
<i>FIGURE 240 BRIC MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	390
Hormone Receptor Drugs	390
FSH, LH AND GNRH Receptor Drugs	390
Overview	391
Revenue	391
<i>TABLE 145 BRIC MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	391
<i>FIGURE 241 BRIC MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	392
Lipid and Phospholipid Receptor Drugs	392
Eicosanoid Receptor Drugs	392
Overview	392
Revenue	393
<i>TABLE 146 BRIC MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	393
<i>FIGURE 242 BRIC MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	393
S1P Receptor Modulators	393
Overview	394
Revenue	394
<i>TABLE 147 BRIC MARKET FOR SPHINGOPHOSPHATE RECEPTOR MODULATORS, THROUGH 2018 (\$ MILLIONS)</i>	394
<i>FIGURE 243 BRIC MARKET FOR SPHINGOPHOSPHATE RECEPTOR MODULATORS, 2010-2018 (\$ MILLIONS)</i>	394
Nucleotide Receptor Drugs	395
P2Y Receptor Antagonists	395
Overview	395
Revenue	395
<i>TABLE 148 BRIC MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	395
<i>FIGURE 244 BRIC MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 (\$ MILLIONS)</i>	395
SECRETIN-LIKE RECEPTOR DRUGS	396
Peptide Receptor Drugs	396
Glucagon-like Peptide (GLP) Receptor Agonists	396
Overview	396
Revenue	397
<i>TABLE 149 BRIC MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	397

TOPIC	PAGE NO.
<i>FIGURE 245 BRIC MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 (\$ MILLIONS)</i>	397
Hormone Receptor Drugs	398
Parathyroid Hormone (PTH) Receptor Agonists	398
Overview	398
Revenue	398
<i>TABLE 150 BRIC MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	398
<i>FIGURE 246 BRIC MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	399
METABOTROPIC GLUTAMATE-LIKE RECEPTOR DRUGS	399
Ion Receptor Drugs	399
Calcium-Sensing Receptor (CaSR) Agonists	399
Overview	399
Revenue	399
<i>TABLE 151 BRIC MARKET FOR CALCIUM-SENSING RECEPTOR MODULATORS, THROUGH 2018 (\$ MILLIONS)</i>	400
<i>FIGURE 247 BRIC MARKET FOR CALCIUM-SENSING RECEPTOR MODULATORS, 2010-2018 (\$ MILLIONS)</i>	400
MARKET ANALYSIS BY THERAPEUTIC APPLICATION	400
CARDIOVASCULAR DRUGS	401
<i>TABLE 152 BRIC MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	401
<i>FIGURE 248 BRIC MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)</i>	401
Anti-Hypertensives	402
Overview	402
Revenue	402
<i>FIGURE 249 BRIC MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)</i>	403
Platelet Aggregation Inhibitors	403
Overview	403
Revenue	403
<i>FIGURE 250 BRIC MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 (\$ MILLIONS)</i>	403
Other Anti-Hypertensives	404
Overview	404
Revenue	404
<i>FIGURE 251 BRIC MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)</i>	404
CENTRAL NERVOUS SYSTEM (CNS) DRUGS	405
<i>TABLE 153 BRIC MARKET FOR GPCR CNS DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	405
<i>FIGURE 252 BRIC MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013 (%)</i>	406
Anti-Psychotics	406
Overview	407
Revenue	407
<i>FIGURE 253 BRIC MARKET FOR gpcr ANTI-PSYCHOTICS, 2010-2018 (\$ MILLIONS)</i>	407
Anti-Parkinson's Drugs	408
Overview	408

TOPIC	PAGE NO.
Revenue	408
<i>FIGURE 254 BRIC MARKET FOR GPCR ANTI-PARKINSON'S, 2010-2018 (\$ MILLIONS)</i>	408
Anti-Migraine Drugs	409
Overview	409
Revenue	409
<i>FIGURE 255 BRIC MARKET FOR GPCR ANTI-MIGRAINES, 2010-2018 (\$ MILLIONS)</i>	409
Nootropics	410
Overview	410
Revenue	410
<i>FIGURE 256 BRIC MARKET FOR GPCR NOOTROPICS, 2010-2018 (\$ MILLIONS)</i>	410
Psychostimulants	411
Overview	411
Revenue	411
<i>FIGURE 257 BRIC MARKET FOR GPCR PSYCHOSTIMULANTS, 2010-2018 (\$ MILLIONS)</i>	411
Analgesics	412
Overview	412
Revenue	412
<i>FIGURE 258 BRIC MARKET FOR GPCR ANALGESICS, 2010-2018 (\$ MILLIONS)</i>	412
Opioid Dependence Medications	413
Overview	413
Revenue	413
<i>FIGURE 259 BRIC MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 (\$ MILLIONS)</i>	413
RESPIRATORY DRUGS	414
<i>TABLE 154 BRIC MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	414
<i>FIGURE 260 BRIC MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013</i>	414
Bronchodilators and Anti-Inflammatories	415
Overview	415
Revenue	415
<i>FIGURE 261 BRIC MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 (\$ MILLIONS)</i>	415
Anti-Allergics	416
Overview	416
Revenue	416
<i>FIGURE 262 BRIC MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 (\$ MILLIONS)</i>	416
IMMUNOLOGY DRUGS	417
<i>TABLE 155 BRIC MARKET FOR IMMUNOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	417
<i>FIGURE 263 BRIC MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013</i>	417
Immunosuppressants	418
Overview	419
Revenue	419
<i>FIGURE 264 BRIC MARKET OF GPCR IMMUNOSUPPRESSANTS, 2010-2018 (\$ MILLIONS)</i>	419
Anti-Retrovirals	419
Overview	420
Revenue	420

TOPIC	PAGE NO.
<i>FIGURE 265 BRIC MARKET OF GPCR ANTI-RETROVIRALS, 2010-2018 (\$ MILLIONS)</i>	420
ENDOCRINOLOGY/METABOLIC DRUGS	420
<i>TABLE 156 BRIC MARKET OF ENDOCRINOLOGY/METABOLICS DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	421
<i>FIGURE 266 BRIC MARKET SHARE OF ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, THROUGH 2018</i>	421
Anti-Diabetics	422
Overview	422
Revenue	422
<i>FIGURE 267 BRIC MARKET FOR GPCR ANTI-DIABETICS, 2010-2018 (\$ MILLIONS)</i>	422
Infertility Treatments	422
Overview	423
Revenue	423
<i>FIGURE 268 BRIC MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 (\$ MILLIONS)</i>	423
Hormone Therapies	423
Overview	424
Revenue	424
<i>FIGURE 269 BRIC MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 (\$ MILLIONS)</i>	424
ONCOLOGY DRUGS	425
<i>TABLE 157 BRIC MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	425
<i>FIGURE 270 BRIC MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013</i>	425
Anti-Neoplastic Agents	426
Overview	426
Revenue	426
<i>FIGURE 271 BRIC MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 (\$ MILLIONS)</i>	426
Anti-Emetics	427
Overview	427
Revenue	427
<i>FIGURE 272 BRIC MARKET FOR GPCR ANTI-EMETICS, 2010-2018 (\$ MILLIONS)</i>	427
GENITOURINARY DRUGS	428
<i>TABLE 158 BRIC MARKET FOR GENITOURINARY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	428
<i>FIGURE 273 BRIC MARKET SHARE OF GPCR GENITOURINARY DRUG COMPANIES, 2013</i>	428
Anti-Diuretics	429
Overview	429
Revenue	429
<i>FIGURE 274 BRIC MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 (\$ MILLION`S)</i>	429
OPHTHALMIC DRUGS	430
Anti-Glaucoma Drugs	430
Overview	430
Revenue	430
<i>TABLE 159 BRIC MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	430
<i>FIGURE 275 BRIC MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 (\$ MILLIONS)</i>	430

TOPIC	PAGE NO.
<i>FIGURE 276 BRIC MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013</i>	431
CHAPTER 10 MARKETS IN THE REST OF THE WORLD	433
MARKET ANALYSIS	433
<i>TABLE 160 ROW MARKET FOR GPCR DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	433
<i>FIGURE 277 ROW MARKET FOR GPCR DRUGS, 2010-2018 (\$ MILLIONS)</i>	434
RHODOPSIN-LIKE RECEPTOR DRUGS	434
Peptide Receptor Drugs	434
Angiotensin II Receptor Antagonists	434
Overview	435
Revenue	435
<i>TABLE 161 ROW MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBs), THROUGH 2018 (\$ MILLIONS)</i>	435
<i>FIGURE 278 ROW MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBs), 2010-2018 (\$ MILLIONS)</i>	435
Bradykinin Receptor Antagonists	436
Overview	436
Revenue	436
<i>TABLE 162 ROW MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	437
<i>FIGURE 279 ROW MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	437
Opioid Receptor Targeting Drugs	437
Overview	438
Revenue	438
<i>TABLE 163 ROW MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	439
<i>FIGURE 280 ROW MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	439
Chemokine Receptor Antagonists	439
Overview	439
Revenue	440
<i>TABLE 164 ROW MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	440
<i>FIGURE 281 ROW MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	440
Somatostatin Receptor Agonists	441
Overview	441
Revenue	441
<i>TABLE 165 ROW MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 (\$ MILLIONS)</i>	441
<i>FIGURE 282 ROW MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 (\$ MILLIONS)</i>	441
Endothelin Receptor Antagonists	442
Overview	442
Revenue	443
<i>TABLE 166 ROW MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	443
<i>FIGURE 283 ROW MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)</i>	443

TOPIC	PAGE NO.
Biogenic Amine Receptor Drugs	443
Muscarinic Receptor Targeting Drugs	443
Overview	444
Revenue	444
<i>TABLE 167 ROW MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	444
<i>FIGURE 284 ROW MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	445
Adrenergic Receptor Targeting Drugs	445
Overview	445
Revenue	445
<i>TABLE 168 ROW MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	446
<i>FIGURE 285 ROW MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	446
Dopamine Receptor Drugs	446
Overview	447
Revenue	447
<i>TABLE 169 ROW MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	447
<i>FIGURE 286 ROW MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	447
Histamine Receptor Antagonists	448
Overview	448
Revenue	448
<i>TABLE 170 ROW MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	449
<i>FIGURE 287 ROW MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	449
Serotonin Receptor Targeting Drugs	449
Overview	449
Revenue	450
<i>TABLE 171 ROW MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	450
<i>FIGURE 288 ROW MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	450
Hormone Receptor Drugs	451
FSH, LH AND GNRH Receptor Drugs	451
Overview	451
Revenue	451
<i>TABLE 172 ROW MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	452
<i>FIGURE 289 ROW MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	452
Lipid and Phospholipid Receptor Drugs	452
Eicosanoid Receptor Drugs	452
Overview	453
Revenue	453
<i>TABLE 173 ROW MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	453

TOPIC	PAGE NO.
<i>FIGURE 290 ROW MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	454
S1P Receptor Modulators	454
Overview	454
Revenue	454
<i>TABLE 174 ROW MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	455
<i>FIGURE 291 ROW MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	455
Nucleotide Receptor Drugs	455
P2Y Receptor Antagonists	455
Overview	456
Revenue	456
<i>TABLE 175 ROW MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	456
<i>FIGURE 292 ROW MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 (\$ MILLIONS)</i>	456
SECRETIN RECEPTOR DRUGS	457
Peptide Receptor Drugs	457
Glucagon-like Peptide (GLP) Receptor Agonists	457
Overview	457
Revenue	457
<i>TABLE 176 ROW MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)</i>	458
<i>FIGURE 293 ROW MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 (\$ MILLIONS)</i>	458
Hormone Receptor Drugs	458
Parathyroid Hormone (PTH) Receptor Agonists	458
Overview	459
Revenue	459
<i>TABLE 177 ROW MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	459
<i>FIGURE 294 ROW MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)</i>	459
METABOTROPIC GLUTAMATE-LIKE RECEPTOR DRUGS	459
Ion Receptor Drugs	460
Calcium-Sensing Receptor (CaSR) Agonists	460
Overview	460
Revenue	460
<i>TABLE 178 ROW MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, THROUGH 2018 (\$ MILLIONS)</i>	460
<i>FIGURE 295 ROW MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, 2010-2018 (\$ MILLIONS)</i>	460
MARKET ANALYSIS BY THERAPEUTIC APPLICATION	461
CARDIOVASCULAR DRUGS	461
<i>TABLE 179 ROW MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	462
<i>FIGURE 296 ROW MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)</i>	462
Anti-Hypertensives	463

TOPIC	PAGE NO.
Overview	463
Revenue	463
<i>FIGURE 297 ROW MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)</i>	463
Platelet Aggregation Inhibitors	464
Overview	464
Revenue	464
<i>FIGURE 298 ROW MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 (\$ MILLIONS)</i>	465
Other Anti-Hypertensives	465
Overview	465
Revenue	466
<i>FIGURE 299 ROW MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)</i>	466
CENTRAL NERVOUS SYSTEM (CNS) DRUGS	466
<i>TABLE 180 ROW MARKET FOR GPCR CNS DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	467
<i>FIGURE 300 ROW MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013</i>	467
Anti-Psychotics	468
Overview	468
Revenue	468
<i>FIGURE 301 ROW MARKET FOR GPCR ANTI-PSYCHOTICS, 2010-2018 (\$ MILLIONS)</i>	469
Anti-Parkinson's Drugs	469
Overview	469
Revenue	469
<i>FIGURE 302 ROW MARKET FOR GPCR ANTI-PARKINSON'S, 2010-2018 (\$ MILLIONS)</i>	469
Anti-Migraine Drugs	470
Overview	470
Revenue	470
<i>FIGURE 303 ROW MARKET FOR GPCR ANTI-MIGRAINES, 2010-2018 (\$ MILLIONS)</i>	470
Nootropics	471
Overview	471
Revenue	471
<i>FIGURE 304 ROW MARKET FOR GPCR NOOTROPICS, 2010-2018 (\$ MILLIONS)</i>	471
Psychostimulants	472
Overview	472
Revenue	472
<i>FIGURE 305 ROW MARKET FOR GPCR PSYCHOSTIMULANTS, 2010-2018 (\$ MILLIONS)</i>	472
Analgesics	473
Overview	473
Revenue	473
<i>FIGURE 306 ROW MARKET FOR GPCR ANALGESICS, 2010-2018 (\$ MILLIONS)</i>	473
Opioid Dependence Medications	474
Overview	474
Revenue	474
<i>FIGURE 307 ROW MARKET FOR GPCR OPIOID DEPENDENCE, 2010-2018 (\$ MILLIONS)</i>	474
RESPIRATORY DRUGS	475

TOPIC	PAGE NO.
<i>TABLE 181 ROW MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	475
<i>FIGURE 308 ROW MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013 (%)</i>	475
Bronchodilators and Anti-Inflammatories	476
Overview	477
Revenue	477
<i>FIGURE 309 ROW MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 (\$ MILLIONS)</i>	477
Anti-Allergics	477
Overview	478
Revenue	478
<i>FIGURE 310 ROW MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 (\$ MILLIONS)</i>	478
IMMUNOLOGY DRUGS	478
<i>TABLE 182 ROW MARKET OF GPCR IMMUNOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	479
<i>FIGURE 311 ROW MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013 (\$ MILLIONS)</i>	479
Immunosuppressants	480
Overview	480
Revenue	480
<i>FIGURE 312 ROW MARKET FOR GPCR IMMUNOSUPPRESSANTS, 2010-2018 (\$ MILLIONS)</i>	480
Anti-Retrovirals	481
Overview	481
Revenue	481
<i>FIGURE 313 ROW MARKET OF GPCR ANTI-RETROVIRALS, 2010-2018 (\$ MILLIONS)</i>	481
ENDOCRINOLOGY/METABOLIC DRUGS	482
<i>TABLE 183 ROW MARKET OF GPCR ENDOCRINOLOGY/METABOLICS DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	482
<i>FIGURE 314 ROW MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, 2013</i>	482
Anti-Diabetics	483
Overview	484
Revenue	484
<i>FIGURE 315 ROW MARKET FOT GPCR ANTI-DIABETICS, 2010-2018 (\$ MILLIONS)</i>	484
Infertility Treatments	484
Overview	485
Revenue	485
<i>FIGURE 316 ROW MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 (\$ MILLIONS)</i>	485
Hormone Therapies	485
Overview	486
Revenue	486
<i>FIGURE 317 ROW MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 (\$ MILLIONS)</i>	486
ONCOLOGY DRUGS	487
<i>TABLE 184 ROW MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	487

TOPIC	PAGE NO.
<i>FIGURE 318 ROW MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013 (%)</i>	487
Anti-Neoplastic Agents	488
Overview	488
Revenue	488
<i>FIGURE 319 ROW MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 (\$ MILLIONS)</i>	488
Anti-Emetics	489
Overview	489
Revenue	489
<i>FIGURE 320 ROW MARKET FOR GPCR ANTI-EMETICS, 2010-2018 (\$ MILLIONS)</i>	489
Hematopoietic Stem Cell Mobilizers	490
Overview	490
Revenue	491
<i>FIGURE 321 ROW MARKET FOR HSC MOBILIZERS, 2010-2018 (\$ MILLIONS)</i>	491
GENITOURINARY DRUGS	491
<i>TABLE 185 ROW MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	491
<i>FIGURE 322 ROW MARKET SHARE OF GENITOURINARY DRUG COMPANIES, THROUGH 2018 (%)</i>	491
Anti-Diuretics	492
Overview	492
Revenue	493
<i>FIGURE 323 ROW MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 (\$ MILLIONS)</i>	493
OPHTHALMIC DRUGS	493
Anti-Glaucoma Drugs	493
Overview	493
Revenue	494
<i>TABLE 186 ROW MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 (\$ MILLIONS)</i>	494
<i>FIGURE 324 ROW MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 (\$ MILLIONS)</i>	494
<i>FIGURE 325 ROW MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013 (%)</i>	494
CHAPTER 11 COMPANY PROFILES	497
ABBOTT LABORATORIES	497
ABBVIE INC.	497
ACTELION PHARMACEUTICALS LTD.	497
ADDEX THERAPEUTICS	498
ALCON INC.	498
ALKERMES PLC.	499
ALLERGAN INC.	499
AMGEN INC.	500
ASTELLAS PHARMA INC.	500
ASTRAZENECA PLC.	500
BOEHRINGER INGELHEIM GMBH	501
BRISTOL-MYERS SQUIBB	502
CHEMOCENTRYX INC.	502
DAIICHI SANKYO CO., LTD.	502

TOPIC	PAGE NO.
DAINIPPON SUMITOMO PHARMA CO., LTD.	503
ELI LILLY AND CO.	504
EMD SERONO INC.	504
ENDO HEALTH SOLUTIONS INC.	504
F. HOFFMANN-LA ROCHE LTD.	505
FOREST LABORATORIES INC.	505
GILEAD SCIENCES INC.	506
GLAXOSMITHKLINE PLC.	506
HELSINN HEALTHCARE S.A.	507
HEPTARES THERAPEUTICS	507
IPSEN S.A.	508
JOHNSON & JOHNSON	508
KYOWA HAKKO KIRIN CO., LTD.	508
LUNDBECK INC.	509
MERCK & CO. INC.	509
DAIICHI SANKYO PHARMA CORP.	510
NEKTAR THERAPEUTICS	510
NOVARTIS INTERNATIONAL AG	511
NOVO NORDISK A.S.	511
NPS PHARMACEUTICALS	512
ONO PHARMACEUTICAL CO., LTD.	512
OREXO AB	512
OTSUKA HOLDINGS CO., LTD.	513
PFIZER INC.	513
PURDUE PHARMA L.P.	514
RECKITT BENCKISER PHARMACEUTICALS INC.	514
RETROPHIN INC.	515
SANOFI S.A.	515
SANTEN PHARMACEUTICAL CO., LTD.	515
SHIRE PLC.	516
TAKEDA PHARMACEUTICAL CO., LTD	516
TREVENA INC.	517
UCB S.A.	517
UNITED THERAPEUTICS CORP.	518
VALEANT PHARMACEUTICALS INTERNATIONAL INC.	518
VIIV HEALTHCARE	519

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR GPCR DRUGS, THROUGH 2018 (\$ MILLIONS)	7
TABLE 1 CLASSIFICATION OF THE GPCR-TARGETING DRUGS	16
TABLE 2 FDA-APPROVED GPCR TARGETING DRUGS, 2010-2014	19
TABLE 3 POSITIVE OPINION GRANTED BY THE EMA TO GPCR TARGETING DRUGS, 2012-2014	21
TABLE 4 BOX WARNINGS ENFORCED BY THE FDA FOR THE USE OF SELECTED GPCR-TARGETING DRUGS	22
TABLE 5 GLOBAL MARKET FOR GPCR DRUGS, THROUGH 2018 (\$ MILLIONS)	28
TABLE 6 ARB'S IN DEVELOPMENT, BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET	31
TABLE 7 GLOBAL MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), THROUGH 2018 (\$ MILLIONS)	33
TABLE 8 GLOBAL MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	34
TABLE 9 OPIOIDS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET	37
TABLE 10 GLOBAL MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	38
TABLE 11 CHEMOKINE RECEPTOR ANTAGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET	40
TABLE 12 GLOBAL MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	40
TABLE 13 SOMATOSTATIN RECEPTOR AGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET	42
TABLE 14 GLOBAL MARKET FOR SOMATOSTATIN RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)	43
TABLE 15 GLOBAL MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	44
TABLE 16 GLOBAL MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	46
TABLE 17 GLOBAL MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	48
TABLE 18 GLOBAL MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	52
TABLE 19 GLOBAL MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	56
TABLE 20 GLOBAL MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	60
TABLE 21 GLOBAL MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	62
TABLE 22 SEROTONIN RECEPTOR ANTAGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET	65
TABLE 23 GLOBAL MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	66
TABLE 24 GLOBAL MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	69
TABLE 25 EICOSANOID RECEPTOR AGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET	72
TABLE 26 GLOBAL MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	72

TABLE HEADING	PAGE NO.
TABLE 27 S1P RECEPTOR MODULATORS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET	74
TABLE 28 GLOBAL MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	74
TABLE 29 GLOBAL MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 (\$ MILLIONS)	76
TABLE 30 GLOBAL MARKET FOR AMYLIN RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)	78
TABLE 31 GLP-1 RECEPTOR AGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET	80
TABLE 32 GLOBAL MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)	81
TABLE 33 GLOBAL MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	82
TABLE 34 GLOBAL MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	85
TABLE 35 GLOBAL MARKET FOR CALCIUM-SENSING RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)	88
TABLE 36 GLOBAL MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 (\$ MILLIONS)	90
TABLE 37 GLOBAL MARKET FOR GPCR CNS DRUGS, THROUGH 2018 (\$ MILLIONS)	102
TABLE 38 GLOBAL MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 (\$ MILLIONS)	117
TABLE 39 GLOBAL MARKET FOR GPCR IMMUNOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)	124
TABLE 40 GLOBAL MARKET FOR GPCR ENDOCRINOLOGY/METABOLIC DRUGS, THROUGH 2018 (\$ MILLIONS)	131
TABLE 41 GLOBAL MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)	138
TABLE 42 GLOBAL MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 (\$ MILLIONS)	146
TABLE 43 GLOBAL MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 (\$ MILLIONS)	151
TABLE 44 U.S. MARKET FOR GPCR DRUGS, THROUGH 2018 (\$ MILLIONS)	155
TABLE 45 U.S. MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBs), THROUGH 2018 (\$ MILLIONS)	157
TABLE 46 U.S. MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	159
TABLE 47 U.S. MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	161
TABLE 48 U.S. MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	162
TABLE 49 U.S. MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 (\$ MILLIONS)	164
TABLE 50 U.S. MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	165
TABLE 51 U.S. MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	166
TABLE 52 U.S. MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	168
TABLE 53 U.S. MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	170

TABLE HEADING	PAGE NO.
TABLE 54 U.S. MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	171
TABLE 55 U.S. MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	174
TABLE 56 U.S. MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	175
TABLE 57 U.S. MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	177
TABLE 58 U.S. MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	179
TABLE 59 U.S. MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	181
TABLE 60 U.S. MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	183
TABLE 61 U.S. MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 (\$ MILLIONS)	184
TABLE 62 U.S. MARKET FOR MARKET FOR AMYLIN RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)	186
TABLE 63 U.S. MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)	188
TABLE 64 U.S. MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	189
TABLE 65 U.S. MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	190
TABLE 66 U.S. MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, THROUGH 2018 (\$ MILLIONS)	192
TABLE 67 U.S. MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 (\$ MILLIONS)	193
TABLE 68 U.S. MARKET FOR GPCR CNS DRUGS, THROUGH 2018 (\$ MILLIONS)	199
TABLE 69 U.S. MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 (\$ MILLIONS)	210
TABLE 70 U.S. MARKET FOR GPCR IMMUNOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)	215
TABLE 71 U.S. MARKET FOR GPCR ENDOCRINOLOGY/METABOLIC DRUGS, THROUGH 2018 (\$ MILLIONS)	218
TABLE 72 U.S. MARKET FOR ONCOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)	224
TABLE 73 U.S. MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 (\$ MILLIONS)	229
TABLE 74 U.S. MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 (\$ MILLIONS)	234
TABLE 75 EU MARKET FOR GPCR DRUGS, THROUGH 2018 (\$ MILLIONS)	237
TABLE 76 EU MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBs), THROUGH 2018 (\$ MILLIONS)	239
TABLE 77 EU MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	241
TABLE 78 EU MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	242
TABLE 79 EU MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	244
TABLE 80 EU MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 (\$ MILLIONS)	245

TABLE HEADING	PAGE NO.
TABLE 81 EU MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	246
TABLE 82 EU MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	248
TABLE 83 EU MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	249
TABLE 84 EU MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	250
TABLE 85 EU MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	252
TABLE 86 EU MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	254
TABLE 87 EU MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	256
TABLE 88 EU MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	257
TABLE 89 EU MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	259
TABLE 90 EU MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	261
TABLE 91 EU MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	262
TABLE 92 EU MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 (\$ MILLIONS)	264
TABLE 93 EU MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)	266
TABLE 94 EU MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	267
TABLE 95 EU MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	268
TABLE 96 EU MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, THROUGH 2018 (\$ MILLIONS)	270
TABLE 97 EU MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 (\$ MILLIONS)	271
TABLE 98 EU MARKET FOR GPCR CNS DRUGS, THROUGH 2018 (\$ MILLIONS)	276
TABLE 99 EU MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 (\$ MILLIONS)	285
TABLE 100 EU MARKET FOR GPCR IMMUNOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)	289
TABLE 101 EU MARKET FOR GPCR ENDOCRINOLOGY/METABOLIC DRUGS, THROUGH 2018 (\$ MILLIONS)	293
TABLE 102 EU MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)	298
TABLE 103 EU MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 (\$ MILLIONS)	303
TABLE 104 EU MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 (\$ MILLIONS)	307
TABLE 105 JAPAN MARKET FOR GPCR DRUGS, THROUGH 2018 (\$ MILLIONS)	310
TABLE 106 JAPAN MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBs), THROUGH 2018 (\$ MILLIONS)	312
TABLE 107 JAPAN MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	314

TABLE HEADING	PAGE NO.
TABLE 108 JAPAN MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	315
TABLE 109 JAPAN MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 (\$ MILLIONS)	316
TABLE 110 JAPAN MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	318
TABLE 111 JAPAN MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	319
TABLE 112 JAPAN MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	320
TABLE 113 JAPAN MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	322
TABLE 114 JAPAN MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	323
TABLE 115 JAPAN MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	325
TABLE 116 JAPAN MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	326
TABLE 117 JAPAN MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	327
TABLE 118 JAPAN MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	329
TABLE 119 JAPAN MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	330
TABLE 120 JAPAN MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	332
TABLE 121 JAPAN MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 (\$ MILLIONS)	333
TABLE 122 JAPAN MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)	335
TABLE 123 JAPAN MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	336
TABLE 124 JAPAN MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, THROUGH 2018 (\$ MILLIONS)	337
TABLE 125 JAPAN MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 (\$ MILLIONS)	339
TABLE 126 JAPAN MARKET FOR GPCR CNS DRUGS, THROUGH 2018 (\$ MILLIONS)	343
TABLE 127 JAPAN MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 (\$ MILLIONS)	351
TABLE 128 JAPAN MARKET FOR IMMUNOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)	355
TABLE 129 JAPAN MARKET FOR GPCR ENDOCRINOLOGY/METABOLICS DRUGS, THROUGH 2018 (\$ MILLIONS)	358
TABLE 130 JAPAN MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)	363
TABLE 131 JAPAN MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 (\$ MILLIONS)	366
TABLE 132 JAPAN MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 (\$ MILLIONS)	370
TABLE 133 BRIC MARKET FOR GPCR DRUGS, THROUGH 2018 (\$ MILLIONS)	373
TABLE 134 BRIC MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBs), THROUGH 2018 (\$ MILLIONS)	375

TABLE HEADING	PAGE NO.
TABLE 135 BRIC MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	377
TABLE 136 BRIC MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	378
TABLE 137 BRIC MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	380
TABLE 138 BRIC MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 (\$ MILLIONS)	381
TABLE 139 BRIC MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	382
TABLE 140 BRIC MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	384
TABLE 141 BRIC MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	385
TABLE 142 BRIC MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	387
TABLE 143 BRIC MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	388
TABLE 144 BRIC MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	389
TABLE 145 BRIC MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	391
TABLE 146 BRIC MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	393
TABLE 147 BRIC MARKET FOR SPHINGOPHOSPHATE RECEPTOR MODULATORS, THROUGH 2018 (\$ MILLIONS)	394
TABLE 148 BRIC MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 (\$ MILLIONS)	395
TABLE 149 BRIC MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)	397
TABLE 150 BRIC MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	398
TABLE 151 BRIC MARKET FOR CALCIUM-SENSING RECEPTOR MODULATORS, THROUGH 2018 (\$ MILLIONS)	400
TABLE 152 BRIC MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 (\$ MILLIONS)	401
TABLE 153 BRIC MARKET FOR GPCR CNS DRUGS, THROUGH 2018 (\$ MILLIONS)	405
TABLE 154 BRIC MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 (\$ MILLIONS)	414
TABLE 155 BRIC MARKET FOR IMMUNOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)	417
TABLE 156 BRIC MARKET OF ENDOCRINOLOGY/METABOLICS DRUGS, THROUGH 2018 (\$ MILLIONS)	421
TABLE 157 BRIC MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)	425
TABLE 158 BRIC MARKET FOR GENITOURINARY DRUGS, THROUGH 2018 (\$ MILLIONS)	428
TABLE 159 BRIC MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 (\$ MILLIONS)	430
TABLE 160 ROW MARKET FOR GPCR DRUGS, THROUGH 2018 (\$ MILLIONS)	433
TABLE 161 ROW MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBs), THROUGH 2018 (\$ MILLIONS)	435
TABLE 162 ROW MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	437

TABLE HEADING	PAGE NO.
TABLE 163 ROW MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	439
TABLE 164 ROW MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	440
TABLE 165 ROW MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 (\$ MILLIONS)	441
TABLE 166 ROW MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 (\$ MILLIONS)	443
TABLE 167 ROW MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	444
TABLE 168 ROW MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	446
TABLE 169 ROW MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	447
TABLE 170 ROW MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	449
TABLE 171 ROW MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	450
TABLE 172 ROW MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	452
TABLE 173 ROW MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	453
TABLE 174 ROW MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	455
TABLE 175 ROW MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 (\$ MILLIONS)	456
TABLE 176 ROW MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 (\$ MILLIONS)	458
TABLE 177 ROW MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 (\$ MILLIONS)	459
TABLE 178 ROW MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, THROUGH 2018 (\$ MILLIONS)	460
TABLE 179 ROW MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 (\$ MILLIONS)	462
TABLE 180 ROW MARKET FOR GPCR CNS DRUGS, THROUGH 2018 (\$ MILLIONS)	467
TABLE 181 ROW MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 (\$ MILLIONS)	475
TABLE 182 ROW MARKET OF GPCR IMMUNOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)	479
TABLE 183 ROW MARKET OF GPCR ENDOCRINOLOGY/METABOLICS DRUGS, THROUGH 2018 (\$ MILLIONS)	482
TABLE 184 ROW MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 (\$ MILLIONS)	487
TABLE 185 ROW MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 (\$ MILLIONS)	491
TABLE 186 ROW MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 (\$ MILLIONS)	494

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR GPCR DRUGS, 2010-2018 (\$ MILLIONS)	8
FIGURE 1 GLOBAL MARKET FOR GPCR DRUGS, 2010-2018 (\$ MILLIONS)	28
FIGURE 2 GLOBAL MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBs), 2010-2018 (\$ MILLIONS)	33
FIGURE 3 GLOBAL MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	34
FIGURE 4 GLOBAL MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	38
FIGURE 5 GLOBAL MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	40
FIGURE 6 GLOBAL MARKET FOR SOMATOSTATIN RECEPTOR AGONISTS, 2010-2018 (\$ MILLIONS)	43
FIGURE 7 GLOBAL MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	44
FIGURE 8 GLOBAL MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	46
FIGURE 9 GLOBAL MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	48
FIGURE 10 GLOBAL MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	52
FIGURE 11 GLOBAL MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	57
FIGURE 12 GLOBAL MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	60
FIGURE 13 GLOBAL MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	63
FIGURE 14 GLOBAL MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	66
FIGURE 15 GLOBAL MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	69
FIGURE 16 GLOBAL MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	72
FIGURE 17 GLOBAL MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	75
FIGURE 18 GLOBAL MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 (\$ MILLIONS)	77
FIGURE 19 GLOBAL MARKET FOR AMYLIN RECEPTOR AGONIST, 2010-2018 (\$ MILLIONS)	78
FIGURE 20 GLOBAL MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 (\$ MILLIONS)	81
FIGURE 21 GLOBAL MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	82
FIGURE 22 GLOBAL MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	85
FIGURE 23 GLOBAL MARKET FOR CALCIUM-SENSING RECEPTOR AGONISTS, 2010-2018 (\$ MILLIONS)	88
FIGURE 24 GLOBAL MARKET SHARE FOR GPCR CARDIOVASCULAR DRUGS, 2013 (%)	89
FIGURE 25 GLOBAL MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)	91
FIGURE 26 REGIONAL MARKETS FOR GPCR CARDIOVASCULAR DRUGS, 2010-2018 (\$ MILLIONS)	91

FIGURE TITLE	PAGE NO.
FIGURE 27 GLOBAL MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)	95
FIGURE 28 GLOBAL MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 (\$ MILLIONS)	97
FIGURE 29 GLOBAL MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)	99
FIGURE 30 GLOBAL MARKET SHARE FOR GPCR CNS DRUGS, 2013 (%)	101
FIGURE 31 GLOBAL MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013 (%)	103
FIGURE 32 REGIONAL MARKETS FOR GPCR CNS DRUGS, 2010-2018 (\$ MILLIONS)	103
FIGURE 33 GLOBAL MARKET FOR GPCR ANTI-PSYCHOTICS, 2010-2018 (\$ MILLIONS)	106
FIGURE 34 GLOBAL MARKET FOR GPCR ANTI-DEPRESSANT DRUGS, 2010-2018 (\$ MILLIONS)	107
FIGURE 35 GLOBAL MARKET FOR GPCR ANTI-PARKINSON'S DRUGS, 2010-2018 (\$ MILLIONS)	109
FIGURE 36 GLOBAL MARKET FOR GPCR ANTI-MIGRAINE DRUGS, 2010-2018 (\$ MILLIONS)	110
FIGURE 37 GLOBAL MARKET FOR GPCR NOOTROPIC DRUGS, 2010-2018 (\$ MILLIONS)	111
FIGURE 38 GLOBAL MARKET FOR GPCR PSYCHOSTIMULANT DRUGS, 2010-2018 (\$ MILLIONS)	113
FIGURE 39 GLOBAL MARKET FOR GPCR ANALGESIC DRUGS, 2010-2018 (\$ MILLIONS)	114
FIGURE 40 GLOBAL MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 (\$ MILLIONS)	115
FIGURE 41 GLOBAL MARKET SHARE OF GPCR RESPIRATORY DRUGS, 2013 (%)	116
FIGURE 42 GLOBAL MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013 (%)	117
FIGURE 43 REGIONAL MARKETS FOR GPCR RESPIRATORY DRUGS, 2010-2018 (\$ MILLIONS)	119
FIGURE 44 GLOBAL MARKET FOR GPCR BRONCHODILATORS, 2010-2018 (\$ MILLIONS)	122
FIGURE 45 GLOBAL MARKET FOR GPCR BRONCHODILATORS, 2010-2018 (\$ MILLIONS)	123
FIGURE 46 GLOBAL MARKET SHARE FOR GPCR IMMUNOLOGY DRUGS, 2013	123
FIGURE 47 GLOBAL MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013 (%)	124
FIGURE 48 REGIONAL MARKETS FOR THE GPCR IMMUNOLOGY DRUGS, 2010-2018 (\$ MILLIONS)	125
FIGURE 49 GLOBAL MARKET FOR GPCR IMMUNOSUPPRESSANTS, 2010-2018 (\$ MILLIONS)	127
FIGURE 50 GLOBAL MARKET FOR GPCR ANTI-RETROVIRALS, 2010-2018 (\$ MILLIONS)	128
FIGURE 51 GLOBAL MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLIC DRUGS, 2013 (%)	130
FIGURE 52 GLOBAL MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLIC DRUG COMPANIES, 2013 (%)	131
FIGURE 53 REGIONAL MARKETS FOR GPCR ENDOCRINOLOGY/METABOLIC DRUGS, 2010-2018 (\$ MILLIONS)	132
FIGURE 54 GLOBAL MARKET FOR GPCR ANTI-DIABETICS, 2010-2018 (\$ MILLIONS)	134
FIGURE 55 GLOBAL MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 (\$ MILLIONS)	135
FIGURE 56 GLOBAL MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 (\$ MILLIONS)	137
FIGURE 57 GLOBAL MARKET SHARE OF GPCR ONCOLOGY DRUGS, 2013	138

FIGURE TITLE	PAGE NO.
FIGURE 58 GLOBAL MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013 (\$ MILLIONS)	139
FIGURE 59 REGIONAL MARKET FOR GPCR ONCOLOGY DRUGS, 2010-2018 (\$ MILLIONS)	140
FIGURE 60 GLOBAL MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 (\$ MILLIONS)	142
FIGURE 61 GLOBAL MARKET FOR GPCR ANTI-EMETICS, 2010-2018 (\$ MILLIONS)	143
FIGURE 62 GLOBAL MARKET FOR GPCR HEMATOPOIETIC STEM CELL MOBILIZERS, 2010-2018 (\$ MILLIONS)	144
FIGURE 63 GLOBAL MARKET SHARE OF GPCR GENITOURINARY DRUGS, 2013 (%)	145
FIGURE 64 GLOBAL MARKET SHARE OF GPCR GENITOURINARY DRUG COMPANIES, 2013 (%)	146
FIGURE 65 REGIONAL MARKET FOR GPCR GENITOURINARY DRUGS, 2010-2018 (\$ MILLIONS)	146
FIGURE 66 GLOBAL MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 (\$ MILLIONS)	148
FIGURE 67 GLOBAL MARKET FOR GPCR DIURETICS, 2010-2018 (\$ MILLIONS)	149
FIGURE 68 GLOBAL MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013 (%)	151
FIGURE 69 REGIONAL MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 (\$ MILLIONS)	152
FIGURE 70 GLOBAL MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 (\$ MILLIONS)	153
FIGURE 71 U.S. MARKET FOR GPCR DRUGS, 2010-2018 (\$ MILLIONS)	156
FIGURE 72 U.S. MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBs), 2010-2018 (\$ MILLIONS)	157
FIGURE 73 U.S. MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	159
FIGURE 74 U.S. MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	161
FIGURE 75 U.S. MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	162
FIGURE 76 U.S. MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 (\$ MILLIONS)	164
FIGURE 77 U.S. MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	165
FIGURE 78 U.S. MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	166
FIGURE 79 U.S. MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	168
FIGURE 80 U.S. MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	170
FIGURE 81 U.S. MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	172
FIGURE 82 U.S. MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	174
FIGURE 83 U.S. MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	175
FIGURE 84 U.S. MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	178
FIGURE 85 U.S. MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	179
FIGURE 86 U.S. MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	181

FIGURE TITLE	PAGE NO.
FIGURE 87 U.S. MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	183
FIGURE 88 U.S. MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 (\$ MILLIONS)	184
FIGURE 89 U.S. MARKET FOR MARKET FOR AMYLIN RECEPTOR AGONISTS, 2010-2018 (\$ MILLIONS)	186
FIGURE 90 U.S. MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 (\$ MILLIONS)	188
FIGURE 91 U.S. MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	189
FIGURE 92 U.S. MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	191
FIGURE 93 U.S. MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, 2010-2018 (\$ MILLIONS)	192
FIGURE 94 U.S. MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)	193
FIGURE 95 U.S. MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)	196
FIGURE 96 U.S. MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 (\$ MILLIONS)	197
FIGURE 97 U.S. MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)	198
FIGURE 98 U.S. MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013	199
FIGURE 99 U.S. MARKET FOR GPCR GPCR ANTI-PSYCHOTICS, 2010-2018 (\$ MILLIONS)	201
FIGURE 100 U.S. MARKET FOR GPCR ANTI-DEPRESSANTS, 2010-2018 (\$ MILLIONS)	202
FIGURE 101 U.S. MARKET FOR GPCR ANTI-PARKINSON'S DRUGS, 2010-2018 (\$ MILLIONS)	203
FIGURE 102 U.S. MARKET FOR GPCR ANTI-MIGRAINE DRUGS, 2010-2018 (\$ MILLIONS)	205
FIGURE 103 U.S. MARKET FOR GPCR NOOTROPICS, 2010-2018 (\$ MILLIONS)	206
FIGURE 104 U.S. MARKET FOR PSYCHOSTIMULANTS, 2010-2018 (\$ MILLIONS)	207
FIGURE 105 U.S. MARKET FOR ANALGESICS, 2010-2018 (\$ MILLIONS)	208
FIGURE 106 U.S. MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 (\$ MILLIONS)	209
FIGURE 107 U.S. MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013 (%)	210
FIGURE 108 U.S. MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 (\$ MILLIONS)	213
FIGURE 109 U.S. MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 (\$ MILLIONS)	214
FIGURE 110 U.S. MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013 (%)	215
FIGURE 111 U.S. MARKET FOR GPCR IMMUNOSUPPRESSANTS, 2010-2018 (\$ MILLIONS)	216
FIGURE 112 U.S. MARKET FOR GPCR ANTI-RETROVIRALS, 2010-2018 (\$ MILLIONS)	217
FIGURE 113 U.S. MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, 2013	219
FIGURE 114 U.S. MARKET FOR GPCR ANTI-DIABETICS, 2010-2018 (\$ MILLIONS)	220
FIGURE 115 U.S. MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 (\$ MILLIONS)	221
FIGURE 116 U.S. MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 (\$ MILLIONS)	224
FIGURE 117 U.S. MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, THROUGH 2018 (%)	225

FIGURE TITLE	PAGE NO.
FIGURE 118 U.S. MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 (\$ MILLIONS)	227
FIGURE 119 U.S. MARKET FOR GPCR ANTI-EMETICS, 2010-2018 (\$ MILLIONS)	227
FIGURE 120 U.S. MARKET FOR GPCR HSCMS, 2010-2018 (\$ MILLIONS)	228
FIGURE 121 U.S. MARKET SHARE OF GPCR GENITOURINARY DRUG COMPANIES, 2013 (%)	229
FIGURE 122 U.S. MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 (\$ MILLIONS)	231
FIGURE 123 U.S. MARKET FOR GPCR DIURETICS, 2010-2018 (\$ MILLIONS)	233
FIGURE 124 U.S. MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 (\$ MILLIONS)	234
FIGURE 125 U.S. MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013 (%)	234
FIGURE 126 EU MARKET FOR GPCR DRUGS, 2010-2018 (\$ MILLIONS)	237
FIGURE 127 EU MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBs), 2010-2018 (\$ MILLIONS)	239
FIGURE 128 EU MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	241
FIGURE 129 EU MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	242
FIGURE 130 EU MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	244
FIGURE 131 EU MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 (\$ MILLIONS)	245
FIGURE 132 EU MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	247
FIGURE 133 EU MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	248
FIGURE 134 EU MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	249
FIGURE 135 EU MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	250
FIGURE 136 EU MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	252
FIGURE 137 EU MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	254
FIGURE 138 EU MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	256
FIGURE 139 EU MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	258
FIGURE 140 EU MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	259
FIGURE 141 EU MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	261
FIGURE 142 EU MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	263
FIGURE 143 EU MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 (\$ MILLIONS)	264
FIGURE 144 EU MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 (\$ MILLIONS)	266
FIGURE 145 EU MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	267
FIGURE 146 EU MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	268
FIGURE 147 EU MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, 2010-2018 (\$ MILLIONS)	270

FIGURE TITLE	PAGE NO.
FIGURE 148 EU MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)	271
FIGURE 149 EU MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)	273
FIGURE 150 EU MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 (\$ MILLIONS)	274
FIGURE 151 EU MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)	276
FIGURE 152 EU MARKET SHARE OF CNS DRUG COMPANIES, 2013 (%)	277
FIGURE 153 EU MARKET FOR GPCR ANTI-PSYCHOTICS, 2010-2018 (\$ MILLIONS)	278
FIGURE 154 EU MARKET FOR GPCR ANTI-PARKINSON'S, 2010-2018 (\$ MILLIONS)	279
FIGURE 155 EU MARKET FOR GPCR ANTI-MIGRAINE DRUGS, 2010-2018 (\$ MILLIONS)	281
FIGURE 156 EU MARKET FOR GPCR NOOTROPICS, 2010-2018 (\$ MILLIONS)	282
FIGURE 157 EU MARKET FOR GPCR PSYCHOSTIMULANTS, 2010-2018 (\$ MILLIONS)	283
FIGURE 158 EU MARKET FOR GPCR ANALGESICS, 2010-2018 (\$ MILLIONS)	284
FIGURE 159 EU MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 (\$ MILLIONS)	285
FIGURE 160 EU MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013	286
FIGURE 161 EU MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 (\$ MILLIONS)	287
FIGURE 162 EU MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 (\$ MILLIONS)	288
FIGURE 163 EU MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013 (\$ MILLIONS)	289
FIGURE 164 EU MARKET FOR GPCR IMMUNOSUPPRESSANTS, 2010-2018 (\$ MILLIONS)	291
FIGURE 165 EU MARKET FOR GPCR ANTI-RETROVIRALS, 2010-2018 (\$ MILLIONS)	292
FIGURE 166 EU MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, 2013	293
FIGURE 167 EU MARKET FOR GPCR ANTI-DIABETICS, 2010-2018 (\$ MILLIONS)	294
FIGURE 168 EU MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 (\$ MILLIONS)	295
FIGURE 169 EU MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 (\$ MILLIONS)	297
FIGURE 170 EU MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013	298
FIGURE 171 EU MARKET FOR GPCR ANTI-NEOPLASTIC AGENTS, 2010-2018 (\$ MILLIONS)	300
FIGURE 172 EU MARKET FOR GPCR ANTI-EMETICS, 2010-2018 (\$ MILLIONS)	301
FIGURE 173 EU MARKET FOR GPCR HSCMS, 2010-2018 (\$ MILLIONS)	302
FIGURE 174 EU MARKET SHARE OF GPCR GENITOURINARY DRUG COMPANIES, 2013 (%)	303
FIGURE 175 EU MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 (\$ MILLIONS)	304
FIGURE 176 EU MARKET FOR GPCR DIURETICS, 2010-2018 (\$ MILLIONS)	305
FIGURE 177 EU MARKET FOR GPCR ANTI-GLAUCOMA AGENTS, 2010-2018 (\$ MILLIONS)	307
FIGURE 178 EU MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013	307
FIGURE 179 JAPAN MARKET FOR GPCR DRUGS, 2010-2018 (\$ MILLIONS)	310
FIGURE 180 JAPAN MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBs), 2010-2018 (\$ MILLIONS)	312
FIGURE 181 JAPAN MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	314
FIGURE 182 JAPAN MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	316

FIGURE TITLE	PAGE NO.
FIGURE 183 JAPAN MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 (\$ MILLIONS)	317
FIGURE 184 JAPAN MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	318
FIGURE 185 JAPAN MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	319
FIGURE 186 JAPAN MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	321
FIGURE 187 JAPAN MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	322
FIGURE 188 JAPAN MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	324
FIGURE 189 JAPAN MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	325
FIGURE 190 JAPAN MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	326
FIGURE 191 JAPAN MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	327
FIGURE 192 JAPAN MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	329
FIGURE 193 JAPAN MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	330
FIGURE 194 JAPAN MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	332
FIGURE 195 JAPAN MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 (\$ MILLIONS)	333
FIGURE 196 JAPAN MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 (\$ MILLIONS)	335
FIGURE 197 JAPAN MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	336
FIGURE 198 JAPAN MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, 2010-2018 (\$ MILLIONS)	338
FIGURE 199 JAPAN MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013	339
FIGURE 200 JAPAN MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)	340
FIGURE 201 JAPAN MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 (\$ MILLIONS)	341
FIGURE 202 JAPAN MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)	342
FIGURE 203 JAPAN MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013	344
FIGURE 204 JAPAN MARKET FOR GPCR ANTI-PSYCHOTICS, 2010-2018 (\$ MILLIONS)	345
FIGURE 205 JAPAN MARKET FOR GPCR ANTI-PARKINSON'S, 2010-2018 (\$ MILLIONS)	346
FIGURE 206 JAPAN MARKET FOR GPCR ANTI-MIGRAINE, 2010-2018 (\$ MILLIONS)	347
FIGURE 207 JAPAN MARKET FOR GPCR NOOTROPICS, THROUGH 2018 (\$ MILLIONS)	348
FIGURE 208 JAPAN MARKET FOR PSYCHOSTIMULANTS, 2010-2018 (\$ MILLIONS)	349
FIGURE 209 JAPAN MARKET FOR GPCR ANALGESICS, 2010-2018 (\$ MILLIONS)	350
FIGURE 210 JAPAN MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 (\$ MILLIONS)	350
FIGURE 211 JAPAN MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013	351
FIGURE 212 JAPAN MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 (\$ MILLIONS)	353

FIGURE TITLE	PAGE NO.
FIGURE 213 JAPAN MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 (\$ MILLIONS)	354
FIGURE 214 JAPAN MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013	355
FIGURE 215 JAPAN MARKET FOR IMMUNOSUPPRESSANTS, 2010-2018 (\$ MILLIONS)	357
FIGURE 216 JAPAN MARKET FOR GPCR ANTI-RETROVIRALS, 2010-2018 (\$ MILLIONS)	357
FIGURE 217 JAPAN MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, 2013	359
FIGURE 218 JAPAN GPCR ANTI-DIABETICS, 2010-2018 (\$ MILLIONS)	360
FIGURE 219 JAPAN GPCR INFERTILITY TREATMENTS, 2010-2018 (\$ MILLIONS)	361
FIGURE 220 JAPAN MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 (\$ MILLIONS)	362
FIGURE 221 JAPAN MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013	363
FIGURE 222 JAPAN MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 (\$ MILLIONS)	364
FIGURE 223 JAPAN MARKET FOR GPCR ANTI-EMETICS, 2010-2018 (\$ MILLIONS)	365
FIGURE 224 JAPAN MARKET SHARE OF GPCR GENITOURINARY DRUG COMPANIES, 2013 (\$ MILLIONS)	366
FIGURE 225 JAPAN MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 (\$ MILLIONS)	368
FIGURE 226 JAPAN MARKET FOR GPCR DIURETICS, 2010-2018 (\$ MILLIONS)	369
FIGURE 227 JAPAN MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 (\$ MILLIONS)	370
FIGURE 228 JAPAN MARKET SHARE OF OPHTHALMIC DRUG COMPANIES, THROUGH 2018	370
FIGURE 229 BRIC MARKET FOR GPCR DRUGS, 2010-2018 (\$ MILLIONS)	373
FIGURE 230 BRIC MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBs), 2010-2018 (\$ MILLIONS)	375
FIGURE 231 BRIC MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	377
FIGURE 232 BRIC MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	378
FIGURE 233 BRIC MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	380
FIGURE 234 BRIC MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 (\$ MILLIONS)	381
FIGURE 235 BRIC MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	383
FIGURE 236 BRIC MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	384
FIGURE 237 BRIC MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	385
FIGURE 238 BRIC MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	387
FIGURE 239 BRIC MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	388
FIGURE 240 BRIC MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	390
FIGURE 241 BRIC MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	392
FIGURE 242 BRIC MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	393
FIGURE 243 BRIC MARKET FOR SPHINGOPHOSPHATE RECEPTOR MODULATORS, 2010-2018 (\$ MILLIONS)	394

FIGURE TITLE	PAGE NO.
FIGURE 244 BRIC MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 (\$ MILLIONS)	395
FIGURE 245 BRIC MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 (\$ MILLIONS)	397
FIGURE 246 BRIC MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	399
FIGURE 247 BRIC MARKET FOR CALCIUM-SENSING RECEPTOR MODULATORS, 2010-2018 (\$ MILLIONS)	400
FIGURE 248 BRIC MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)	401
FIGURE 249 BRIC MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)	403
FIGURE 250 BRIC MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 (\$ MILLIONS)	403
FIGURE 251 BRIC MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)	404
FIGURE 252 BRIC MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013 (%)	406
FIGURE 253 BRIC MARKET FOR GPCR ANTI-PSYCHOTICS, 2010-2018 (\$ MILLIONS)	407
FIGURE 254 BRIC MARKET FOR GPCR ANTI-PARKINSON'S, 2010-2018 (\$ MILLIONS)	408
FIGURE 255 BRIC MARKET FOR GPCR ANTI-MIGRAINES, 2010-2018 (\$ MILLIONS)	409
FIGURE 256 BRIC MARKET FOR GPCR NOOTROPICS, 2010-2018 (\$ MILLIONS)	410
FIGURE 257 BRIC MARKET FOR GPCR PSYCHOSTIMULANTS, 2010-2018 (\$ MILLIONS)	411
FIGURE 258 BRIC MARKET FOR GPCR ANALGESICS, 2010-2018 (\$ MILLIONS)	412
FIGURE 259 BRIC MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 (\$ MILLIONS)	413
FIGURE 260 BRIC MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013	414
FIGURE 261 BRIC MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 (\$ MILLIONS)	415
FIGURE 262 BRIC MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 (\$ MILLIONS)	416
FIGURE 263 BRIC MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013	417
FIGURE 264 BRIC MARKET OF GPCR IMMUNOSUPPRESSANTS, 2010-2018 (\$ MILLIONS)	419
FIGURE 265 BRIC MARKET OF GPCR ANTI-RETROVIRALS, 2010-2018 (\$ MILLIONS)	420
FIGURE 266 BRIC MARKET SHARE OF ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, THROUGH 2018	421
FIGURE 267 BRIC MARKET FOR GPCR ANTI-DIABETICS, 2010-2018 (\$ MILLIONS)	422
FIGURE 268 BRIC MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 (\$ MILLIONS)	423
FIGURE 269 BRIC MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 (\$ MILLIONS)	424
FIGURE 270 BRIC MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013	425
FIGURE 271 BRIC MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 (\$ MILLIONS)	426
FIGURE 272 BRIC MARKET FOR GPCR ANTI-EMETICS, 2010-2018 (\$ MILLIONS)	427
FIGURE 273 BRIC MARKET SHARE OF GPCR GENITOURINARY DRUG COMPANIES, 2013	428
FIGURE 274 BRIC MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 (\$ MILLIONS)	429
FIGURE 275 BRIC MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 (\$ MILLIONS)	430
FIGURE 276 BRIC MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013	431
FIGURE 277 ROW MARKET FOR GPCR DRUGS, 2010-2018 (\$ MILLIONS)	434
FIGURE 278 ROW MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBs), 2010-2018 (\$ MILLIONS)	435
FIGURE 279 ROW MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	437

FIGURE TITLE	PAGE NO.
FIGURE 280 ROW MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	439
FIGURE 281 ROW MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	440
FIGURE 282 ROW MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 (\$ MILLIONS)	441
FIGURE 283 ROW MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 (\$ MILLIONS)	443
FIGURE 284 ROW MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	445
FIGURE 285 ROW MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	446
FIGURE 286 ROW MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	447
FIGURE 287 ROW MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	449
FIGURE 288 ROW MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	450
FIGURE 289 ROW MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	452
FIGURE 290 ROW MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	454
FIGURE 291 ROW MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	455
FIGURE 292 ROW MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 (\$ MILLIONS)	456
FIGURE 293 ROW MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 (\$ MILLIONS)	458
FIGURE 294 ROW MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 (\$ MILLIONS)	459
FIGURE 295 ROW MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, 2010-2018 (\$ MILLIONS)	460
FIGURE 296 ROW MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)	462
FIGURE 297 ROW MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)	463
FIGURE 298 ROW MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 (\$ MILLIONS)	465
FIGURE 299 ROW MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 (\$ MILLIONS)	466
FIGURE 300 ROW MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013	467
FIGURE 301 ROW MARKET FOR GPCR ANTI-PSYCHOTICS, 2010-2018 (\$ MILLIONS)	469
FIGURE 302 ROW MARKET FOR GPCR ANTI-PARKINSON'S, 2010-2018 (\$ MILLIONS)	469
FIGURE 303 ROW MARKET FOR GPCR ANTI-MIGRAINES, 2010-2018 (\$ MILLIONS)	470
FIGURE 304 ROW MARKET FOR GPCR NOOTROPICS, 2010-2018 (\$ MILLIONS)	471
FIGURE 305 ROW MARKET FOR GPCR PSYCHOSTIMULANTS, 2010-2018 (\$ MILLIONS)	472
FIGURE 306 ROW MARKET FOR GPCR ANALGESICS, 2010-2018 (\$ MILLIONS)	473
FIGURE 307 ROW MARKET FOR GPCR OPIOID DEPENDENCE, 2010-2018 (\$ MILLIONS)	474
FIGURE 308 ROW MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013 (%)	475
FIGURE 309 ROW MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 (\$ MILLIONS)	477

FIGURE TITLE	PAGE NO.
FIGURE 310 ROW MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 (\$ MILLIONS)	478
FIGURE 311 ROW MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013 (\$ MILLIONS)	479
FIGURE 312 ROW MARKET FOR GPCR IMMUNOSUPPRESSANTS, 2010-2018 (\$ MILLIONS)	480
FIGURE 313 ROW MARKET OF GPCR ANTI-RETROVIRALS, 2010-2018 (\$ MILLIONS)	481
FIGURE 314 ROW MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, 2013	482
FIGURE 315 ROW MARKET FOR GPCR ANTI-DIABETICS, 2010-2018 (\$ MILLIONS)	484
FIGURE 316 ROW MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 (\$ MILLIONS)	485
FIGURE 317 ROW MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 (\$ MILLIONS)	486
FIGURE 318 ROW MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013 (%)	487
FIGURE 319 ROW MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 (\$ MILLIONS)	488
FIGURE 320 ROW MARKET FOR GPCR ANTI-EMETICS, 2010-2018 (\$ MILLIONS)	489
FIGURE 321 ROW MARKET FOR HSC MOBILIZERS, 2010-2018 (\$ MILLIONS)	491
FIGURE 322 ROW MARKET SHARE OF GENITOURINARY DRUG COMPANIES, THROUGH 2018 (%)	491
FIGURE 323 ROW MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 (\$ MILLIONS)	493
FIGURE 324 ROW MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 (\$ MILLIONS)	494
FIGURE 325 ROW MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013 (%)	494